Blood Pressure Effects of Sodium Reduction: Dose-Response Meta-Analysis of Experimental Studies by Filippini, Tommaso et al.
April 20, 2021 Circulation. 2021;143:1542–1567. DOI: 10.1161/CIRCULATIONAHA.120.0503711542
Circulation
Tommaso Filippini , MD
Marcella Malavolti , BSc, 
PhD
Paul K. Whelton , MB, 
MD, MSc
Androniki Naska , PhD
Nicola Orsini , PhD
Marco Vinceti , MD, PhD
https://www.ahajournals.org/journal/circ
Key Words: blood pressure ◼ diet  
◼ hypertension ◼ meta-analysis  
◼ public health ◼ sodium ◼ systematic 
review
Sources of Funding, see page 1563
© 2021 The Authors. Circulation is 
published on behalf of the American 
Heart Association, Inc., by Wolters 
Kluwer Health, Inc. This is an open 
access article under the terms of 
the Creative Commons Attribution 
Non-Commercial-NoDerivs License, 
which permits use, distribution, and 
reproduction in any medium, provided 
that the original work is properly cited, 
the use is noncommercial, and no 
modifications or adaptations are made.
Editorial, see p 1568
BACKGROUND: The relationship between dietary sodium intake and blood 
pressure (BP) has been tested in clinical trials and nonexperimental human 
studies, indicating a direct association. The exact shape of the dose–response 
relationship has been difficult to assess in clinical trials because of the lack 
of random-effects dose–response statistical models that can include 2-arm 
comparisons.
METHODS: After performing a comprehensive literature search for 
experimental studies that investigated the BP effects of changes in dietary 
sodium intake, we conducted a dose–response meta-analysis using the new 
1-stage cubic spline mixed-effects model. We included trials with at least 
4 weeks of follow-up; 24-hour urinary sodium excretion measurements; 
sodium manipulation through dietary change or supplementation, or both; 
and measurements of systolic and diastolic BP at the beginning and end of 
treatment.
RESULTS: We identified 85 eligible trials with sodium intake ranging from 
0.4 to 7.6 g/d and follow-up from 4 weeks to 36 months. The trials were 
conducted in participants with hypertension (n=65), without hypertension 
(n=11), or a combination (n=9). Overall, the pooled data were compatible with 
an approximately linear relationship between achieved sodium intake and mean 
systolic as well as diastolic BP, with no indication of a flattening of the curve 
at either the lowest or highest levels of sodium exposure. Results were similar 
for participants with or without hypertension, but the former group showed 
a steeper decrease in BP after sodium reduction. Intervention duration (≥12 
weeks versus 4 to 11 weeks), type of study design (parallel or crossover), use 
of antihypertensive medication, and participants’ sex had little influence on 
the BP effects of sodium reduction. Additional analyses based on the BP effect 
of difference in sodium exposure between study arms at the end of the trial 
confirmed the results on the basis of achieved sodium intake.
CONCLUSIONS: In this dose–response analysis of sodium reduction in clinical 
trials, we identified an approximately linear relationship between sodium 
intake and reduction in both systolic and diastolic BP across the entire range 
of dietary sodium exposure. Although this occurred independently of baseline 
BP, the effect of sodium reduction on level of BP was more pronounced in 
participants with a higher BP level.
Blood Pressure Effects of Sodium 
Reduction
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The association between dietary sodium intake and blood pressure (BP) is one of the most widely in-vestigated and relevant issues for nutritionists and 
cardiovascular disease (CVD) epidemiologists.1–4 Early 
clinical trial reports of systolic BP (SBP) and diastolic BP 
(DBP) reduction after experimental exposure to lower 
levels of dietary sodium intake in humans through a 
randomized controlled trial (RCT) design were first pub-
lished in the 1980s and 1990s, and a large number of 
such studies has been published to date.2–10 Compre-
hensive reviews of the observational evidence both in 
children and in adults have consistently identified a pos-
itive association across a wide range of intake,11,12 al-
though this type of evidence is limited by 2 major meth-
odologic issues: potential for exposure misclassification 
and unmeasured confounding. The World Health Orga-
nization, professional societies, government agencies, 
and guidelines recommend sodium intake reduction 
for prevention and management of high BP.13–20 How-
ever, the strength of the sodium–BP relationship has 
been challenged by some investigators, particularly in 
individuals without hypertension3,21 and for DBP.2 To our 
knowledge, no previous meta-analysis has been able to 
fully characterize the shape of the dose–response rela-
tionship throughout the entire range of dietary sodium 
exposure while adequately taking into account hetero-
geneity across the studies. This deficit can be explained 
by lack of a flexible modeling framework capable of 
incorporating studies encompassing fewer than 3 lev-
els of exposure, as in 2-arm RCTs,2 to assess the dose–
response influence of changes in sodium intake on BP 
levels. Previous reports have ignored either heterogene-
ity across the studies or the shape of the dose–response 
relationship. In general, linear dose–response meta-re-
gressions of RCT results2,3 or forest plots on the basis 
of RCT subgroup pooling4,8 have been computed and 
presented to describe the sodium–BP relationship in hu-
mans. Two reports have presented results of a nonlin-
ear dose–response analysis but they are limited because 
they only studied SBP effects, were based on differ-
ences in sodium exposure between the study arms but 
not on overall (achieved) sodium intake, and assumed a 
single common dose–response relationship underlying 
multiple studies by using a fixed-effects model.10,19
A 1-stage or mixed-effects framework suitable for 
synthesis of tables of empirical contrasts has recently 
become available,22,23 with the key advantage that even 
studies with a single comparison can be included in the 
estimation of heterogeneous and possibly curvilinear 
dose–response relationships. Given the importance of 
this issue for its public health implications, that is, the 
central role of high BP as a risk factor for CVD, particu-
larly stroke, coronary heart disease, and heart failure,15 
the recent availability of a novel statistical approach 
prompted us to design a dose–response meta-analysis 
of trials to explore the effect of sodium intake on BP 
over a wide range of exposure, also stratifying for fac-
tors of interest.
METHODS
All supporting data are available within the article and its Data 
Supplement.
Literature Search
We conducted a systematic search of online databases (PubMed/
MEDLINE, EMBASE, and CENTRAL [Cochrane Central Register 
of Controlled Trials]) through October 12, 2020, for reports of 
RCTs that had tested the effect of dietary sodium reduction 
on BP levels. No language restriction was applied. We used as 
key terms “sodium” and “blood pressure.” Detailed search 
strategies are reported in Table I in the Data Supplement. We 
checked the reference lists of articles generated by the search 
and performed backward and forward citation chasing to iden-
tify other eligible publications. Title and abstract screening and 
subsequent full-text evaluation were performed in duplicate 
by 2 authors (Drs Filippini and Malavolti). A third author (Dr 
Vinceti) helped resolve differences.
Clinical Perspective
What Is New?
• A comprehensive dose–response meta-analysis of 
trials detailing the effects of changes in dietary 
sodium on blood pressure (BP), using the most up-
to-date statistical dose–response modeling, shows 
that the relationship is positive, and almost but not 
entirely linear.
• The sodium change–BP relationship was present in 
analyses of long-term trials, although slightly atten-
uated compared with the corresponding finding in 
short-term studies, and was noted in both analy-
ses based on differences in sodium intake between 
study arms and achieved sodium intake.
• Higher background sodium consumption and BP 
increase strength and steepness of the effects on 
BP by changes in sodium intake.
What Are the Clinical Implications?
• The clinical implications of a substantially linear 
positive relationship between sodium intake and 
BP even in the long-term trials are that a progres-
sively large reduction in BP can be expected with 
decreases in sodium consumption down to lev-
els as low as 1 to 1.5 g/d, with no evidence for a 
threshold in benefit.
• Advice to reduce dietary sodium intake applies 
not only to adults with hypertension, who can be 
expected to derive a substantial reduction in BP, 
but also to those without hypertension, in whom 
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Using PECO (population, exposure, comparator, and 
outcomes) recommendations,24 the eligibility inclusion crite-
ria were (1) participants with and without hypertension but 
excluding secondary hypertension; (2) intervention performed 
comparing low sodium exposure with high sodium exposure 
within an experimental dietary intervention encompass-
ing either sodium reduction compared with normal diet or 
sodium reduction followed by supplementation with sodium 
or placebo tablets; (3) comparator being normal/high sodium 
diet or placebo administration, without mixed intervention 
components in which contribution of sodium could not be 
determined; (4) SBP or DBP, or both, measured as an outcome 
of interest; (5) 24-hour urinary sodium excretion measured 
before and after the intervention; and (6) trial duration of at 
least 4 weeks. Use of a salt substitute that partially replaced 
sodium with potassium was considered an exclusion criterion 
if the intervention had been administrated to 1 group only. 
When relevant data were missing, we sought to contact study 
authors for retrieval of the necessary information so it could 
be included in the review.
Risk of Bias Assessment
We conducted an independent assessment of study quality 
using the revised Risk of Bias assessment tool version 2.0.25 
The following 5 risk of bias domains were considered: (1) ran-
domization process errors; (2) deviations from the intended 
interventions; (3) missing outcome data; (4) measurement of 
the outcome; and (5) selection of the reported result. Each 
domain could be characterized as having a low risk of bias, 
some concerns, or a high risk of bias. A study was assigned an 
overall higher risk of bias if it was judged to be at higher risk 
for at least 1 domain and an intermediate risk of bias when 
some concern existed in at least 1 domain.
Data Extraction
We extracted the following data from included studies: first 
author name, publication year, country, duration of sodium 
intervention phase, number of participants and characteristics 
(including among other factors hypertension status and use of 
antihypertensive medication), study design (crossover or paral-
lel), modality of BP measurement (type of device: manual or 
automatic, and position: supine, sitting, standing, 24-hour, oth-
ers), type of sodium intervention, baseline and achieved sodium 
excretion level, and SBP and DBP mean difference between 
intervention and control groups, along with the SE at the end 
of the intervention periods. When SE was not directly reported, 
it was calculated from SD, CI, or exact P value following the 
Cochrane Handbook for Systematic Reviews of Interventions.26
Records identified through online 





























Records excluded after 
title/abstract screening
(n = 5836)
Full-text articles assessed for 
eligibility
(n = 146)
Full-text articles excluded, with reasons (n = 61)
- sodium excretion or blood pressure levels not 
reported (n = 25)
- duplicate studies on same population (n = 18)
- duration less than 4 weeks (n = 7)
- not trial with sodium intervention (n = 10)
- use of salt substitute in one group only (n = 1)
Studies included in 
qualitative synthesis
(n = 85)
Studies included in 
quantitative synthesis 
(meta-analysis)
(n = 85) 
Duplicates excluded
(n = 762) 
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We performed a random-effects dose–response meta-analysis 
assessing the relationship between changes in sodium excre-
tion or overall sodium excretion at the end of the trial and 
changes in SBP and DBP levels using the 1-stage mixed effect 
meta-analytic model for aggregated data recently described 
in detail.22,23,27,28 We used restricted cubic splines of sodium 
with 3 knots at fixed percentiles (10%, 50%, and 90%) 
having no a priori assumptions regarding the shape of the 
association. No constraints were imposed on the variances or 
covariance of the random effects placed on the 2 regression 
coefficients of the splines. For comparison, we also modeled 
sodium using a simpler linear function, which is nested within 
the restricted cubic spline function. Estimates of the mea-
sures were obtained with the restricted maximum likelihood 
method.22,29 Statistical inference was primarily based on the 
summary dose–response relationship.
We used level of sodium excretion at the end of the trial 
in each arm as achieved sodium excretion and net differ-
ence between urinary sodium excretion at the end minus the 
beginning of the trial in each randomized arm as difference in 
sodium excretion. We defined the mean difference in BP after 
the intervention as the difference for either SBP or DBP at 
the end minus the corresponding baseline value in the active 
and control arms of the trial. We used a reference value of 
87 mmol/d, which corresponds to 2 g of sodium (or 5 g of 
salt), the value recently defined as safe and adequate intake 
for the European adult population by the European Food 
Safety Authority20 and not to be exceeded by World Health 
Organization13 and European professional societies,18 being 
also close to the slightly lower14,17 and higher19 values defined 
by US bodies. We assumed sodium excretion to be identical 
to sodium intake (or exposure) in this article, on the basis of 
the very small difference between the 2 values in individuals 
and populations.20
We carried out stratified analyses based on study design 
(parallel versus crossover), hypertension status, use of antihy-
pertensive medication, and length of follow-up. In a sensitiv-
ity analysis, we excluded trials at high risk for bias.
We examined small-study bias by using funnel plots and 
the Egger test. The Egger test aims to measure bias direction 
and magnitude using the intercept from a linear regression 
analysis between the effect estimate against its SE.30 Intercept 
values <0.6, from 0.4 to 1.0, from 0.8 to 2.0, and >1.8 have 
been suggested as indicators of unimportant, moderate, sub-
stantial, and considerable small-study effects, respectively.31 
We also used the trim-and-fill method by including the 
observed studies to estimate the suppressed studies in order 
to correct for small-study effects based on funnel plot asym-
metry.32 Both analyses were based on the restricted maximum 
likelihood random effects method. We used Stata statistical 
software (v16.1, StataCorp, College Station, TX) for our data 
analysis, including the meta routine and the 1-stage approach 
based on the drmeta command.23,27,33
RESULTS
The PRISMA (Preferred Reporting Items for System-
atic Reviews and Meta-Analyses) literature search 
flowchart is presented in Figure 1. We retrieved 6744 
publication titles, and after title and abstract screening, 
evaluation of 146 full-text reports resulted in identifi-
cation of 85 trial articles that could be included in the 
analysis. Reasons for exclusion included absence of ei-
ther 24-hour urinary sodium measurements or BP lev-
els (n=25), duplicate reports on the same population 
(n=18), duration <4 weeks (n=7), determination that 
sodium reduction was not the trial intervention (n=10), 
and use of a salt substitute containing potassium in 
the intervention but not in the control group (n=1). 
Table 1 presents selected characteristics of the 85 trials 
included in the analysis.34–118 The reports, which were 
published between 1973 and 2018, were based on an 
overall sample size >10 000 participants and included 
trials conducted in Europe (n=40), Oceania (n=21), 
North America (n=17), Asia (n=6), and Africa (n=1). 
Most of the trials (n=76) included men and women, 
but sex stratification of the results was only available 
in 4 reports. One study included only women and 7 
studies only men. The mean age ranged from 23 to 
73 years (overall range, 18 to 82 years). Parallel and 
crossover designs were equally represented, with only 
3 of the latter including a washout period of 1 or 2 
weeks. Most trials were limited to participants with 
hypertension (n=65), but 11 were conducted in par-
ticipants without hypertension and 9 included adults 
with and without hypertension, in 2 cases presenting a 
stratified analysis by hypertension status and in 2 oth-
ers an analysis restricted to participants without hyper-
tension. In trials including participants with hyperten-
sion, treatment with antihypertensive medication was 
either continued during the trial (n=35) or discontin-
ued (n=28); in 6 trials, results both with and without 
antihypertensive treatment were presented. Sodium 
intervention included sodium reduction and then ad-
ministration of a sodium-containing supplement to 
1 arm (n=43), or diet modification through a broad 
spectrum of interventions aimed at achieving sodium 
reduction (n=38); in 2 trials, both dietary modification 
and sodium supplementations were used. Dietary ad-
vice for sodium reduction ranged from instructions not 
to add salt during cooking and at the table, suggestion 
of dietary regimens as well as tailored diets prepared 
by a dietitian, to more complex and sophisticated in-
terventions. Examples of the latter include small group 
counseling for several weeks, followed by large group 
counseling, and individualized monitoring and feed-
back to assist participants in achieving and maintaining 
the desired interventions. Types and modalities of trial 
interventions are detailed in Table II in the Data Supple-
ment. In almost all of the trials that included sodium 
supplementation, dietary intake of sodium had been 
restricted before the trial, and sodium supplements 
ranged from 50 to 190 mmol/d (1.1 to 4.4 g/d), but 
most of the trials implemented an amount of 80 to 
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Table 1. Study Characteristics of the 85 Trials Included in the Analysis Table 1. Continued
Reference Year Country Duration Population Sex





sive medication BP device BP modality Intervention type
Alli et al (1992)34 1992 Italy 12 months 26t and 30c Both 48 Parallel — Yes No Manual Supine Diet
Ames (2001)35 (group 1, nondiabetic/
group 2, diabetic)
2001 United States 4 weeks 13/8 Both (60 to 61) Crossover No Yes Yes Manual Seated Supplementation
Andersson et al (1984)36 1984 Sweden 9 to 11 weeks 10t and 13c Men 51 (41 to 59) Parallel — Yes No Manual Supine Supplementation
Australian National Health and Medical 
Research Council Dietary Salt Study Man-
agement Committee et al (1989)37
1989 Australia 8 weeks 50t and 53c Both 58 (45 to 69) Parallel — Yes No Manual Seated Supplementation
Australian National Health and Medical 
Research Council Dietary Salt Study Man-
agement Committee et al (1989)38
1989 Australia 8 weeks 44 Both 59 Crossover No Yes No Automatic Seated Supplementation
Appel et al (2001)39 2001 United States 3.5 months 317t and 296c Both (60 to 80) Parallel — Yes No Manual Seated Diet
Arroll and Beaglehole (1995)40 1995 New Zealand 6 months 44t and 43c/48t and 46c Both 55 (20 to 69) Parallel — Yes Yes Manual Seated Diet
Beard et al (1982)41 1982 Australia 12 weeks 45t and 45c Both 49 Parallel — Yes Yes Manual Rest Diet
Benetos et al (1992)42 1992 France 9 weeks 20 Both 42 (22 to 55) Crossover Yes (1 wk) Yes No Automatic Supine Supplementation
Bulpitt et al (1984)43 1984 United Kingdom 3 months 32t and 33c Both 54 Parallel — Yes Yes Manual Supine and standing Diet
Cappuccio et al (1997)44 1997 United Kingdom 4 weeks 47 Both 67 (60 to 78) Crossover No Both (no + yes) No Automatic Supine and standing Supplementation
Cappuccio et al (2006)45 2006 Ghana 6 months 399t and 402c Both 55 (40 to 70) Parallel — Both Yes Not reported Not reported Diet
Carney et al (1991)46 1991 Australia 6 weeks 11 Both 54 (30 to 65) Crossover No Yes Yes (with and 
without diuretics)
Manual Supine and standing Supplementation
Chalmers et al (1986)47
 (diet phase/group 1/group 2/group 3/
group 4/group 5/group 6)
1986 Australia 4 weeks 48t and 52c/
11t and 9c/23t and 20c/13t 
and 11c/24t and 23c/13t 
and 14c/9t and 10c
Both 52 Parallel — Yes No Automatic Seated Diet, 
supplementation
Cobiac et al (1992)48 (group 1/group 2) 1992 Australia 4 weeks 26t and 28c/25t and 27c Both 67 (60 to 80) Parallel — No — Automatic Seated Supplementation
De Keyzer et al (2015)49 2015 Belgium 28 days 23 Both 64 (52 to 77) Crossover No Yes Yes Manual Rest Diet
de Vries et al (2016)50 2016 The Netherlands 6 weeks 22 Both 58 Crossover No Yes Yes Automatic Supine Diet
Dickinson et al (2014)51 2014 Australia 6 weeks 25 Both (40 to 70) Crossover No No — Automatic Seated and 24-hours Supplementation
Dodson et al (1989)52 (phase 1/phase 2) 1989 United Kingdom 3 months/1 month 17t and 17c/9 Both 62 Parallel crossover No Yes Yes Manual Supine and standing Diet, supplementation
Erwteman et al (1984)53 (phase 1/phase 2/
phase 3/phase 4)
1984 The Netherlands 4 weeks 50t and 44c Men 46 (20 to 70) Parallel — Yes No/yes/yes/yes Manual Supine and standing Diet
Fagerberg et al (1984)54 1984 Sweden 9 to 12 weeks 15t and 15c Men 51 Parallel — Yes No Automatic and manual Supine and intra-arterial Supplementation
Fagerberg et al (1985)55 1985 Sweden 9 to 11 weeks 10t and 8c Men 51 Parallel — Yes No Automatic and manual Supine and intra-arterial Supplementation
Fagerberg et al (1985)56 1985 Sweden 9 to 12 weeks 15t and 15c Men 51 Parallel — Yes No Automatic and manual Supine and intra-arterial Supplementation
Fotherby and Potter (1993)57 1993 United Kingdom 5 weeks 17 Both 73 (66 to 79) Crossover No Yes No Manual Supine and standing Supplementation
Gates et al (2004)58 2004 United States 4 weeks 12 Both 63 Crossover No Yes No Automatic Rest Supplementation
Gijsbers et al (2015)59 2015 The Netherlands 4 weeks 36 Both 66 (40 to 80) Crossover No Yes No Automatic Supine Supplementation
Gillies et al (1984)60 1984 Australia 6 weeks 24 Both 57 Crossover No Yes Yes Manual Supine and standing Diet
Grobbee et al (1987)61 1987 Netherlands 12 weeks 34 Both 24 (18 to 28) Crossover No Yes Yes Manual Supine Supplementation
He et al (2010)62 2010 United Kingdom 6 weeks 169 Both 50 (30 to 75) Crossover No Yes No Automatic Seated and 24-hour Supplementation
He et al (2015)63 2015 China 3.5 months 271t and 261c Both 44 Parallel — No — Automatic Seated Diet
Howe et al (1994)64 (group 1/group 2) 1994 Australia 6 weeks 14t and 14c/14t and 14c Both 55 (34 to 82) Parallel — Yes Yes Automatic Seated Supplementation
Hypertension Prevention Trial Research 
Group (1990)65
1990 United States 3 years 174t and 177c Both 39 Parallel — Both No Manual Seated Diet
Hwang et al (2014)66 2014 South Korea 8 weeks 119t and 126c Both 49 Parallel — Yes Yes Not reported Not reported Diet
Jablonski et al (2013)67 2013 United States 5 weeks 17 Both 60 (51 to 77) Crossover No Yes Yes Automatic Seated Supplementation
James et al (1994)68 1994 United States 4 weeks 19 Both 50 Crossover No Yes No Automatic and manual Seated Diet
James et al (1996)69 (men/women) 1996 United States 4 weeks 24/8 Both (51 to 57) Crossover No Yes No Manual Seated Diet
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Table 1. Study Characteristics of the 85 Trials Included in the Analysis Table 1. Continued
Reference Year Country Duration Population Sex





sive medication BP device BP modality Intervention type
Alli et al (1992)34 1992 Italy 12 months 26t and 30c Both 48 Parallel — Yes No Manual Supine Diet
Ames (2001)35 (group 1, nondiabetic/
group 2, diabetic)
2001 United States 4 weeks 13/8 Both (60 to 61) Crossover No Yes Yes Manual Seated Supplementation
Andersson et al (1984)36 1984 Sweden 9 to 11 weeks 10t and 13c Men 51 (41 to 59) Parallel — Yes No Manual Supine Supplementation
Australian National Health and Medical 
Research Council Dietary Salt Study Man-
agement Committee et al (1989)37
1989 Australia 8 weeks 50t and 53c Both 58 (45 to 69) Parallel — Yes No Manual Seated Supplementation
Australian National Health and Medical 
Research Council Dietary Salt Study Man-
agement Committee et al (1989)38
1989 Australia 8 weeks 44 Both 59 Crossover No Yes No Automatic Seated Supplementation
Appel et al (2001)39 2001 United States 3.5 months 317t and 296c Both (60 to 80) Parallel — Yes No Manual Seated Diet
Arroll and Beaglehole (1995)40 1995 New Zealand 6 months 44t and 43c/48t and 46c Both 55 (20 to 69) Parallel — Yes Yes Manual Seated Diet
Beard et al (1982)41 1982 Australia 12 weeks 45t and 45c Both 49 Parallel — Yes Yes Manual Rest Diet
Benetos et al (1992)42 1992 France 9 weeks 20 Both 42 (22 to 55) Crossover Yes (1 wk) Yes No Automatic Supine Supplementation
Bulpitt et al (1984)43 1984 United Kingdom 3 months 32t and 33c Both 54 Parallel — Yes Yes Manual Supine and standing Diet
Cappuccio et al (1997)44 1997 United Kingdom 4 weeks 47 Both 67 (60 to 78) Crossover No Both (no + yes) No Automatic Supine and standing Supplementation
Cappuccio et al (2006)45 2006 Ghana 6 months 399t and 402c Both 55 (40 to 70) Parallel — Both Yes Not reported Not reported Diet
Carney et al (1991)46 1991 Australia 6 weeks 11 Both 54 (30 to 65) Crossover No Yes Yes (with and 
without diuretics)
Manual Supine and standing Supplementation
Chalmers et al (1986)47
 (diet phase/group 1/group 2/group 3/
group 4/group 5/group 6)
1986 Australia 4 weeks 48t and 52c/
11t and 9c/23t and 20c/13t 
and 11c/24t and 23c/13t 
and 14c/9t and 10c
Both 52 Parallel — Yes No Automatic Seated Diet, 
supplementation
Cobiac et al (1992)48 (group 1/group 2) 1992 Australia 4 weeks 26t and 28c/25t and 27c Both 67 (60 to 80) Parallel — No — Automatic Seated Supplementation
De Keyzer et al (2015)49 2015 Belgium 28 days 23 Both 64 (52 to 77) Crossover No Yes Yes Manual Rest Diet
de Vries et al (2016)50 2016 The Netherlands 6 weeks 22 Both 58 Crossover No Yes Yes Automatic Supine Diet
Dickinson et al (2014)51 2014 Australia 6 weeks 25 Both (40 to 70) Crossover No No — Automatic Seated and 24-hours Supplementation
Dodson et al (1989)52 (phase 1/phase 2) 1989 United Kingdom 3 months/1 month 17t and 17c/9 Both 62 Parallel crossover No Yes Yes Manual Supine and standing Diet, supplementation
Erwteman et al (1984)53 (phase 1/phase 2/
phase 3/phase 4)
1984 The Netherlands 4 weeks 50t and 44c Men 46 (20 to 70) Parallel — Yes No/yes/yes/yes Manual Supine and standing Diet
Fagerberg et al (1984)54 1984 Sweden 9 to 12 weeks 15t and 15c Men 51 Parallel — Yes No Automatic and manual Supine and intra-arterial Supplementation
Fagerberg et al (1985)55 1985 Sweden 9 to 11 weeks 10t and 8c Men 51 Parallel — Yes No Automatic and manual Supine and intra-arterial Supplementation
Fagerberg et al (1985)56 1985 Sweden 9 to 12 weeks 15t and 15c Men 51 Parallel — Yes No Automatic and manual Supine and intra-arterial Supplementation
Fotherby and Potter (1993)57 1993 United Kingdom 5 weeks 17 Both 73 (66 to 79) Crossover No Yes No Manual Supine and standing Supplementation
Gates et al (2004)58 2004 United States 4 weeks 12 Both 63 Crossover No Yes No Automatic Rest Supplementation
Gijsbers et al (2015)59 2015 The Netherlands 4 weeks 36 Both 66 (40 to 80) Crossover No Yes No Automatic Supine Supplementation
Gillies et al (1984)60 1984 Australia 6 weeks 24 Both 57 Crossover No Yes Yes Manual Supine and standing Diet
Grobbee et al (1987)61 1987 Netherlands 12 weeks 34 Both 24 (18 to 28) Crossover No Yes Yes Manual Supine Supplementation
He et al (2010)62 2010 United Kingdom 6 weeks 169 Both 50 (30 to 75) Crossover No Yes No Automatic Seated and 24-hour Supplementation
He et al (2015)63 2015 China 3.5 months 271t and 261c Both 44 Parallel — No — Automatic Seated Diet
Howe et al (1994)64 (group 1/group 2) 1994 Australia 6 weeks 14t and 14c/14t and 14c Both 55 (34 to 82) Parallel — Yes Yes Automatic Seated Supplementation
Hypertension Prevention Trial Research 
Group (1990)65
1990 United States 3 years 174t and 177c Both 39 Parallel — Both No Manual Seated Diet
Hwang et al (2014)66 2014 South Korea 8 weeks 119t and 126c Both 49 Parallel — Yes Yes Not reported Not reported Diet
Jablonski et al (2013)67 2013 United States 5 weeks 17 Both 60 (51 to 77) Crossover No Yes Yes Automatic Seated Supplementation
James et al (1994)68 1994 United States 4 weeks 19 Both 50 Crossover No Yes No Automatic and manual Seated Diet
James et al (1996)69 (men/women) 1996 United States 4 weeks 24/8 Both (51 to 57) Crossover No Yes No Manual Seated Diet
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Kwakernaak et al (2014)71 (phase 1/
phase 2)
2014 The Netherlands 6 weeks 45 Both 65 Crossover No Yes Yes (ACEI)/yes 
(ACEI - HCT)
Automatic Supine Diet
Lee et al (2018)72 2018 South Korea 8 weeks 30t and 28c Both 43 (>20) Parallel — Yes No Automatic Rest and 24-hour Diet
MacGregor et al (1982)73 1982 United Kingdom 4 weeks 19 Both 49 (30 to 66) Crossover No Yes No Automatic Supine and standing Supplementation
MacGregor et al (1987)74 1987 United Kingdom 1 months 15 Both 52 (33 to 71) Crossover No Yes Yes Automatic Supine and standing Supplementation
MacGregor et al (1989)75 1989 United Kingdom 4 weeks 20 Both 57 (42 to 72) Crossover No Yes No Automatic Supine and standing Supplementation
Mascioli et al (1991)76 (group 1, sodium 
first/group 2, placebo first)
1991 United States 4 weeks 25 Both 52 Crossover Yes (2 wk) No — Manual Seated Supplementation
Maxwell et al (1984)77 1984 United States 12 weeks 18t and 12c Both 47 Parallel — Yes No Manual Seated Supplementation
McCarron et al (1997)78 1997 United States 4 weeks 99 Both 52 Crossover No Yes Yes Manual Seated Supplementation
Meland et al (1997)79 1997 Norway 8 weeks 16 Both 50 (20 to 69) Crossover No Yes No Manual Seated Supplementation
Meland and Aamland (2009)80 2009 Norway 8 weeks 23 Both 56 (20 to 75) Parallel — Yes Yes Manual Seated Supplementation
Melander et al (2007)81 (group 1/group 2) 2007 Sweden 4 weeks 21/18 Both 53 Crossover No Yes/no No Automatic Supine Supplementation
Morgan and Myers (1981)82 (group 1/
group 2)
1981 Australia 4 weeks 6t and 6c/6t and 6c Both (28 to 50) Parallel — Yes Yes Manual Rest Diet
Morgan and Nowson (1987)83 1987 Australia 26 weeks 10t and 10c Men 60 (50 to 65) Parallel — Yes Yes Automatic Rest Diet
Mühlhauser et al (1996)84 1996 Germany 4 weeks 8t and 8c Both 36 (18 to 60) Parallel — Yes No Manual Rest Supplementation
Nakano et al (2016)85 2016 Japan 12 weeks 51t and 44c Both 59 Parallel — Yes Yes Automatic Rest and 24-hour Diet
Nestel et al (1993)86 (group 1/group 2) 1993 Australia 6 weeks 17t and 19c/15t and 15c Both 66 (60 to 79) Parallel — No — Automatic Seated Supplementation
Nowson and Morgan (1988)87 (group 1/
group 2)
1988 Australia 12 weeks 52t and 55c/53t and 52c Both 52 Parallel — Yes No Automatic Seated Diet
Nowson et al (2003)88 2003 Australia 4 weeks 108 Both 47 Crossover No Both (and no) Both Automatic Rest Supplementation
Nowson et al (2009)89 2009 Australia 14 weeks 46t and 49t Women 59 Parallel — Both (no + yes) Yes Automatic Seated Diet
Parijs et al (1973)90 (group 1/group 2) 1973 Belgium 4 weeks 18/18 Both 41 Crossover No Yes No/yes Automatic and manual Supine and standing Diet
Parker et al (1990)91 (group 1/group 2) 1990 Australia 4 weeks 15t and 13c/16t and 15c Men 53 (20 to 70)/50 
(20 to 70)
Parallel — Yes Yes Automatic Supine and standing Supplementation
Parvanova et al (2018)92 2018 Italy 3 months 57t and 58c Both 64 Parallel — Yes Yes Not reported Not reported Diet
Pinjuh Markota et al (2015)93 2015 Croatia 2 months 76t and 74c Both 59 Parallel — Yes No Manual Rest Diet
Puska et al (1983)94 1983 Finland 6 weeks 34t and 38c Both (30 to 50) Parallel No Both No Automatic Seated Diet
Redón- Más et al (1993)95 1993 Spain 28 days 235t and 183c Both 55 Parallel — Yes Yes Manual Seated Diet
Resnick et al (1994)96 (group 1, salt-sensi-
tive/group 2, salt-insensitive)
1994 United States 1 months 9/10 Both 57 Crossover No Yes Both (no + yes) Manual Rest Diet
Richards et al (1984)97 1984 New Zealand 4 to 6 weeks 12 Both (19 to 52) Crossover No Yes No Automatic Supine, standing, and 
intra-arterial
Supplementation
Ruppert et al (1993)98 1993 Germany 4 weeks 25 Both 47 (27 to 75) Crossover No No — Automatic Seated Supplementation
Sacks et al (2001)99 (group 1/group 2) 2001 United States 4 weeks 198/192 Both 48 (>22) Crossover No Both No Manual Seated Diet
Schorr et al (1996)100 (group 1/group 2) 1996 Germany 4 weeks 16 Both (60 to 72) Crossover No No — Automatic Rest Supplementation
Sciarrone et al (1992)101 1992 Australia 8 weeks 44t and 42c Both 53 (20 to 69) Parallel — Yes Yes Automatic Supine and standing Supplementation
Silman et al (1983)102 1983 United Kingdom 12 months 12t and 15c Both (50 to 64) Parallel — Yes No Manual Rest Diet
Singer et al (1991)103 1991 United Kingdom 4 weeks 21 Both 54 Crossover No Yes Yes Automatic Supine and standing Supplementation
Slagman et al (2011)104 2011 The Netherlands 8 weeks 52 Both 51 Crossover No Yes Yes Automatic Supine Diet
Suckling et al (2016)105 2016 United Kingdom 6 weeks 46 Both 58 (30 to 80) Crossover No Yes No Automatic and manual Seated and 24-hour Supplementation
Svetkey et al (2009)106 (group 1, GP in-
volved/group 2, GP not involved)
2009 United States 18 months 124t and 122c/128t and 
134c
Both 60 Parallel — Yes Yes Automatic Seated Diet
Swift et al (2005)107 2005 United Kingdom 4 weeks 40 Both 50 Crossover No Yes No Automatic Supine and 24-hour Supplementation
Takahashi et al (2006)108 2006 Japan 1 year 119t and 116c Both 56 (20 to 69) Parallel — Both Both Manual Rest Diet
Trials of Hypertension Prevention (2012)109 2012 Australia 4 weeks 23 Both 44 (24 to 61) Crossover Yes (2 wk) No — Automatic Seated Supplementation
Table 1. Continued Table 1. Continued
Reference Year Country Duration Population Sex
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Kwakernaak et al (2014)71 (phase 1/
phase 2)
2014 The Netherlands 6 weeks 45 Both 65 Crossover No Yes Yes (ACEI)/yes 
(ACEI - HCT)
Automatic Supine Diet
Lee et al (2018)72 2018 South Korea 8 weeks 30t and 28c Both 43 (>20) Parallel — Yes No Automatic Rest and 24-hour Diet
MacGregor et al (1982)73 1982 United Kingdom 4 weeks 19 Both 49 (30 to 66) Crossover No Yes No Automatic Supine and standing Supplementation
MacGregor et al (1987)74 1987 United Kingdom 1 months 15 Both 52 (33 to 71) Crossover No Yes Yes Automatic Supine and standing Supplementation
MacGregor et al (1989)75 1989 United Kingdom 4 weeks 20 Both 57 (42 to 72) Crossover No Yes No Automatic Supine and standing Supplementation
Mascioli et al (1991)76 (group 1, sodium 
first/group 2, placebo first)
1991 United States 4 weeks 25 Both 52 Crossover Yes (2 wk) No — Manual Seated Supplementation
Maxwell et al (1984)77 1984 United States 12 weeks 18t and 12c Both 47 Parallel — Yes No Manual Seated Supplementation
McCarron et al (1997)78 1997 United States 4 weeks 99 Both 52 Crossover No Yes Yes Manual Seated Supplementation
Meland et al (1997)79 1997 Norway 8 weeks 16 Both 50 (20 to 69) Crossover No Yes No Manual Seated Supplementation
Meland and Aamland (2009)80 2009 Norway 8 weeks 23 Both 56 (20 to 75) Parallel — Yes Yes Manual Seated Supplementation
Melander et al (2007)81 (group 1/group 2) 2007 Sweden 4 weeks 21/18 Both 53 Crossover No Yes/no No Automatic Supine Supplementation
Morgan and Myers (1981)82 (group 1/
group 2)
1981 Australia 4 weeks 6t and 6c/6t and 6c Both (28 to 50) Parallel — Yes Yes Manual Rest Diet
Morgan and Nowson (1987)83 1987 Australia 26 weeks 10t and 10c Men 60 (50 to 65) Parallel — Yes Yes Automatic Rest Diet
Mühlhauser et al (1996)84 1996 Germany 4 weeks 8t and 8c Both 36 (18 to 60) Parallel — Yes No Manual Rest Supplementation
Nakano et al (2016)85 2016 Japan 12 weeks 51t and 44c Both 59 Parallel — Yes Yes Automatic Rest and 24-hour Diet
Nestel et al (1993)86 (group 1/group 2) 1993 Australia 6 weeks 17t and 19c/15t and 15c Both 66 (60 to 79) Parallel — No — Automatic Seated Supplementation
Nowson and Morgan (1988)87 (group 1/
group 2)
1988 Australia 12 weeks 52t and 55c/53t and 52c Both 52 Parallel — Yes No Automatic Seated Diet
Nowson et al (2003)88 2003 Australia 4 weeks 108 Both 47 Crossover No Both (and no) Both Automatic Rest Supplementation
Nowson et al (2009)89 2009 Australia 14 weeks 46t and 49t Women 59 Parallel — Both (no + yes) Yes Automatic Seated Diet
Parijs et al (1973)90 (group 1/group 2) 1973 Belgium 4 weeks 18/18 Both 41 Crossover No Yes No/yes Automatic and manual Supine and standing Diet
Parker et al (1990)91 (group 1/group 2) 1990 Australia 4 weeks 15t and 13c/16t and 15c Men 53 (20 to 70)/50 
(20 to 70)
Parallel — Yes Yes Automatic Supine and standing Supplementation
Parvanova et al (2018)92 2018 Italy 3 months 57t and 58c Both 64 Parallel — Yes Yes Not reported Not reported Diet
Pinjuh Markota et al (2015)93 2015 Croatia 2 months 76t and 74c Both 59 Parallel — Yes No Manual Rest Diet
Puska et al (1983)94 1983 Finland 6 weeks 34t and 38c Both (30 to 50) Parallel No Both No Automatic Seated Diet
Redón- Más et al (1993)95 1993 Spain 28 days 235t and 183c Both 55 Parallel — Yes Yes Manual Seated Diet
Resnick et al (1994)96 (group 1, salt-sensi-
tive/group 2, salt-insensitive)
1994 United States 1 months 9/10 Both 57 Crossover No Yes Both (no + yes) Manual Rest Diet
Richards et al (1984)97 1984 New Zealand 4 to 6 weeks 12 Both (19 to 52) Crossover No Yes No Automatic Supine, standing, and 
intra-arterial
Supplementation
Ruppert et al (1993)98 1993 Germany 4 weeks 25 Both 47 (27 to 75) Crossover No No — Automatic Seated Supplementation
Sacks et al (2001)99 (group 1/group 2) 2001 United States 4 weeks 198/192 Both 48 (>22) Crossover No Both No Manual Seated Diet
Schorr et al (1996)100 (group 1/group 2) 1996 Germany 4 weeks 16 Both (60 to 72) Crossover No No — Automatic Rest Supplementation
Sciarrone et al (1992)101 1992 Australia 8 weeks 44t and 42c Both 53 (20 to 69) Parallel — Yes Yes Automatic Supine and standing Supplementation
Silman et al (1983)102 1983 United Kingdom 12 months 12t and 15c Both (50 to 64) Parallel — Yes No Manual Rest Diet
Singer et al (1991)103 1991 United Kingdom 4 weeks 21 Both 54 Crossover No Yes Yes Automatic Supine and standing Supplementation
Slagman et al (2011)104 2011 The Netherlands 8 weeks 52 Both 51 Crossover No Yes Yes Automatic Supine Diet
Suckling et al (2016)105 2016 United Kingdom 6 weeks 46 Both 58 (30 to 80) Crossover No Yes No Automatic and manual Seated and 24-hour Supplementation
Svetkey et al (2009)106 (group 1, GP in-
volved/group 2, GP not involved)
2009 United States 18 months 124t and 122c/128t and 
134c
Both 60 Parallel — Yes Yes Automatic Seated Diet
Swift et al (2005)107 2005 United Kingdom 4 weeks 40 Both 50 Crossover No Yes No Automatic Supine and 24-hour Supplementation
Takahashi et al (2006)108 2006 Japan 1 year 119t and 116c Both 56 (20 to 69) Parallel — Both Both Manual Rest Diet
Trials of Hypertension Prevention (2012)109 2012 Australia 4 weeks 23 Both 44 (24 to 61) Crossover Yes (2 wk) No — Automatic Seated Supplementation
Table 1. Continued Table 1. Continued
Reference Year Country Duration Population Sex
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24-hour sodium excretion in each study arm, both at 
baseline and at the end of the trial. The difference in 
sodium excretion between intervention and control 
groups ranged from to 5 to 309 mmol/d (0.1 to 7.1 
g/d) with a median value of ≈80 mmol/d (1.8 g/d). The 
level of achieved sodium intake at the end of the trials 
ranged from 17 to 330 mmol, ie, 0.4 to 7.6 g/d.
Risk of bias assessment is presented in Table III in 
the Data Supplement. Almost all studies resulted in in-
termediate risk of bias because of lack of evidence of 
randomization process or missing information about 
concealment methods. Two trials, both carried out in 
hypertensive participants and using dietary modifica-
tion, resulted in a high risk of bias caused by deviations 
from the intended interventions34 or use of an unblind-
ed study design.49
In the dose–response assessment of the effect 
of achieved sodium intake on BP levels, we used 87 
mmol/d, corresponding to 2 g/d of sodium intake, as 
the reference value. In Tables 2 and 3, we report the 
SBP and DBP differences estimated by means of ran-
dom-effects dose–response spline regression models 
from this cut point of exposure at different levels of 
sodium excretion, ie, for 0.5 g increases starting at 1.5 
g/d, also taking into account some study characteris-
tics that were effect modifiers. We observed gener-
ally stronger dose–response relationships for both SBP 
and DBP in trials based on overall dietary modification 
compared with those based on sodium supplementa-
tion, in both instances with a steeper dose-response 
for SBP compared with DBP across the entire range of 
sodium excretion. We also found a stronger BP effect 
of achieved sodium intake in participants with hyper-
tension compared with those with normal BP and in 
women compared with men. In an analysis based on 
the overall range of exposure (Figure 2), achieved so-
dium excretion was positively and almost linearly asso-
ciated with changes in SBP and DBP over a wide range 
of intake (0 to 300 mmol/d of sodium excretion), al-
though the curve for SBP was steeper than for DBP. 
The overall BP difference over the entire range of so-
dium exposure was >15 mm Hg for SBP and nearly 10 
mm Hg for DBP. In linear regression analysis, every 100 
mmol/d reduction in urinary sodium excretion was as-
sociated with a lower mean SBP of 5.56 mm Hg (95% 
CI, −4.52 to −6.59) and a lower mean DBP of 2.33 
mm Hg (95% CI, −1.66 to −3.00). In the trials that 
used sodium supplementation, the mean (95% CI) de-
crease in BP for a 100 mmol/d reduction in sodium ex-
cretion was 4.47 mm Hg (95% CI, −3.08 to −5.86) for 
SBP and 1.90 mm Hg (95% CI, −0.99 to −2.81) for DBP 
and the corresponding reduction in the trials that used 
a behavior change intervention was 6.63 mm Hg (95% 
CI, −5.12 to −8.15) for SBP and 2.79 mm Hg (95% CI, 
−1.80 to −3.78) for DBP. Similarly, every 1 g/d decrease 
of sodium excretion was associated with a lower mean 
(95% CI) SBP and DBP of 2.42 mm Hg (95% CI, −1.97 
to −2.87) and 1.01 mm Hg (95% CI, −0.72 to −1.31), 
respectively. Corresponding values of mean (95% CI) 
SBP and DBP reduction were 1.94 mm Hg (95% CI, 
−1.34 to −2.55) and 0.83 mm Hg (95% CI, −0.43 to 
−1.22) in the studies where initial dietary sodium re-
duction was followed by sodium supplementation in 
the control arm and 2.88 mm Hg (95% CI, −2.23 to 
−3.54) and 1.21 mm Hg (95% CI, −0.78 to −1.64) in 
studies where sodium reduction was achieved by di-
etary modification.
Figure 3 shows the dose–response range according 
to presence or absence of hypertension at baseline. 
Both subgroups showed a tendency for BP lowering af-
ter a reduction in dietary sodium and a roughly linear 
association between achieved sodium intake and BP 
change at the end of the trials, with the exception that 
there was little evidence of BP effect in the participants 
without hypertension whose sodium intake was <2 g/d. 
The participants with hypertension had a much steeper 
Trials of Hypertension Prevention (1992)110 1992 United States 12 months 327t and 417c Both 43 (30 to 54) Parallel — No — Manual Seated Diet
Trials of Hypertension Prevention (1997)111 
(group 1/group 2)
1997 United States 36 months 515t and 514c/537t and 
527c
Both 43 (30 to 54) Parallel — No — Manual Seated Diet
van Berge-Landry and James (2004)112 2004 United States 4 weeks 48 Both 51 Crossover No Yes No Manual Seated Diet
Vogt et al (2008)113 (phase 1/phase 2/
phase 3)
2008 The Netherlands 6 weeks 33 Both 50 (23 to 68) Crossover No Yes No/yes/yes Automatic Supine Diet
Watt et al (1983)114 1983 United Kingdom 4 weeks 18 Both 52 (31 to 64) Crossover No Yes No Manual Seated Supplementation
Watt et al (1985)115 (group 1, both parents 
high BP/group 2, both parents low BP)
1985 United Kingdom 4 weeks 31/35 Both 23 Crossover No No — Manual Seated Supplementation
Weir et al (2010)116 2010 United States 4 weeks 115 Both 51 Crossover No Yes Yes Automatic and manual Seated and 24-hour Diet
Wing et al (1998)117 (group 1/group 2) 1998 Australia 6 weeks 17/17 Both 61 (37 to 74) Crossover No Yes No/yes Automatic 24-hour Supplementation
Yamamoto (1997)118 1997 Japan 6 weeks 18t and 18c Both 60 (40 to 69) Parallel — Yes Yes Automatic Seated and 24-hour Diet
(Continued ) ACEI indicates angiotensin-converting enzyme inhibitor; BP, blood pressure; c, control group; GP, general practitioner; HCT, hydrochlorothiazide; and t, treated group.
Table 1. Continued Table 1. Continued
Reference Year Country Duration Population Sex
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Trials of Hypertension Prevention (1992)110 1992 United States 12 months 327t and 417c Both 43 (30 to 54) Parallel — No — Manual Seated Diet
Trials of Hypertension Prevention (1997)111 
(group 1/group 2)
1997 United States 36 months 515t and 514c/537t and 
527c
Both 43 (30 to 54) Parallel — No — Manual Seated Diet
van Berge-Landry and James (2004)112 2004 United States 4 weeks 48 Both 51 Crossover No Yes No Manual Seated Diet
Vogt et al (2008)113 (phase 1/phase 2/
phase 3)
2008 The Netherlands 6 weeks 33 Both 50 (23 to 68) Crossover No Yes No/yes/yes Automatic Supine Diet
Watt et al (1983)114 1983 United Kingdom 4 weeks 18 Both 52 (31 to 64) Crossover No Yes No Manual Seated Supplementation
Watt et al (1985)115 (group 1, both parents 
high BP/group 2, both parents low BP)
1985 United Kingdom 4 weeks 31/35 Both 23 Crossover No No — Manual Seated Supplementation
Weir et al (2010)116 2010 United States 4 weeks 115 Both 51 Crossover No Yes Yes Automatic and manual Seated and 24-hour Diet
Wing et al (1998)117 (group 1/group 2) 1998 Australia 6 weeks 17/17 Both 61 (37 to 74) Crossover No Yes No/yes Automatic 24-hour Supplementation
Yamamoto (1997)118 1997 Japan 6 weeks 18t and 18c Both 60 (40 to 69) Parallel — Yes Yes Automatic Seated and 24-hour Diet
(Continued ) ACEI indicates angiotensin-converting enzyme inhibitor; BP, blood pressure; c, control group; GP, general practitioner; HCT, hydrochlorothiazide; and t, treated group.
Table 1. Continued Table 1. Continued
Reference Year Country Duration Population Sex





sive medication BP device BP modality Intervention type
dose-response for mean SBP and mean DBP over the 
entire range of achieved sodium excretion, and there-
fore at the highest and the lowest exposure levels the 
BP differences were considerably larger compared with 
those seen in the participants without hypertension. The 
BP changes at the extremes of sodium intake were more 
statistically imprecise for those without hypertension 
(based on 15 studies) than for those with hypertension 
(based on 67 studies), with wider CIs for the point esti-
mates particularly at the lowest exposure levels for DBP. 
At a sodium intake as high as 6 g/d compared with 2 
g/d, in participants without hypertension, mean (95% 
CI) SBP and DBP increases were 3.99 mm Hg (95% CI, 
+0.80 to +7.18) and 1.66 mm Hg (95% CI, −0.58 to 
+3.91), respectively. In participants with hypertension, 
the corresponding differences were 10.31 mm Hg (95% 
CI, +7.86 to +12.75) and 5.13 mm Hg (95% CI, +3.52 
to +6.74). Based on use of a linear function in partici-
pants without hypertension, a 100 mmol/d decrease in 
sodium intake was associated with a reduction in mean 
(95% CI) SBP and DBP of 2.30 mm Hg (95% CI, −1.33 
to −3.27) and 0.80 mm Hg (95% CI, +0.29 to −1.89), re-
spectively. The corresponding SBP and DBP reductions in 
participants with hypertension were 6.50 mm Hg (95% 
CI, −5.22 to −7.79) and 3.00 mm Hg (95% CI, −2.27 
to −3.74), respectively. Limited differences emerged 
when we further stratified the trials according to the 
method used to achieve the intervention effect (sodium 
restriction followed by supplementation versus dietary 
modification through behavior change; Figure I in the 
Data Supplement) and the hypertensive status. Similar 
results were obtained in participants with hypertension 
whether or not they were being treated with antihyper-
tensive drug therapy, except for a higher SBP level for 
those with a very high sodium intake who were receiv-
ing antihypertensive drug therapy (Figure II in the Data 
Supplement), particularly in those subject to a dietary in-
tervention (Figure III in the Data Supplement). When we 
stratified the analysis according to a baseline SBP <140 
mm Hg versus ≥140 mm Hg in participants with hyper-
tension, we found substantially similar BP effects for 
both categories of sodium intake (Figure IV in the Data 
Supplement). A 100 mmol/d decrease in sodium intake 
was associated with a reduction in mean (95% CI) SBP 
and DBP of 7.79 mm Hg (95% CI, −4.90 to −10.67) and 
of 3.10 mm Hg (95% CI, −1.37 to −4.83), respectively, 
in the trial participants with a baseline SBP <140 mm Hg, 
and of 6.06 mm Hg (95% CI, −4.64 to −7.48) and 2.99 
mm Hg (95% CI, −2.17 to −3.81) in the trial participants 
with a baseline SBP ≥140 mm Hg. However, a stronger 
effect on BP (particularly SBP) was noted at higher so-
dium intake (>4 g/d) in participants with hypertension 
whose SBP was <140 or ≥140 mm Hg, after exclusion of 
individuals taking antihypertensive medication (Figure V 
in the Data Supplement).
When we stratified according to baseline sodium 
excretion (<109 mmol/d versus ≥109 mmol/d, ie, <2.5 
g/d versus ≥2.5 g/d), we found stronger BP effects of 
increased sodium intake in participants with higher 
background usual sodium dietary intake for both SBP 
and DBP (Figure VI in the Data Supplement).
When we considered trial duration (4 to 11 weeks 
versus ≥12 weeks), the dose–response relationship 
demonstrated some differences across time and BP end 
point (Figure  4). The gradient for SBP was steeper in 
short-term studies. The gradient for DBP was consider-
ably steeper at medium to high levels of urinary sodium 
excretion in the studies with a duration <12 weeks 
compared with ≥12 weeks, but the reverse was true 
at lower levels of urinary sodium during the conduct 
of the trial. Further exploration by baseline presence 
or absence of hypertension yielded similar results with 
a steeper dose–response slope for the shorter studies 
in participants with hypertension; the corresponding 
dose–response slope in the shorter studies conducted 
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Table 2. Dose–Response Relationship Between Achieved Sodium Excretion and Systolic Blood Pressure Table 2. Continued
Participants N
1.5 g/65 mmol per day
2.0 g/87 
mmol per day
2.5 g/109 mmol per day 3.0 g/130 mmol per day 3.5 g/152 mmol per day 4.0 g/174 mmol per day
Mean difference (95% CI) Mean difference (95% CI) Mean difference (95% CI) Mean difference (95% CI) Mean difference (95% CI)
All 85 −1.28 (−1.77 to −0.79) Ref +1.26 (+0.84 to +1.69) +2.49 (+1.79 to +3.20) +3.66 (+2.84 to +4.48) +4.79 (+3.89 to +5.69)
By type of intervention
 Supplementation 45 −0.86 (−1.46 to −0.26) Ref +0.89 (+0.39 to +1.38) +1.84 (+1.04 to +2.64) +2.87 (+1.92 to +3.82) +3.97 (+2.72 to +5.22)
 Diet 42 −1.64 (−2.41 to −0.87) Ref +1.60 (+0.92 to +2.28) +3.11 (+1.95 to +4.26) +4.46 (+3.11 to +5.82) +5.69 (+4.28 to +7.09)
By hypertension status
 No hypertension 15 −0.50 (−0.87 to −0.12) Ref +0.50 (+0.19 to +0.80) +1.00 (+0.50 to +1.49) +1.49 (+0.81 to +2.18) +1.99 (+0.92 to +3.06)
 Hypertension 67 −1.58 (−2.30 to −0.86) Ref +1.54 (+0.92 to +2.16) +3.01 (+1.99 to +4.02) +4.35 (+3.23 to +5.47) +5.60 (+4.53 to +6.67)
By study design
 Parallel 42 −1.27 (−1.94 to −0.59) Ref +1.23 (+0.63 to +1.83) +2.37 (+1.36 to +3.39) +3.38 (+2.17 to +4.59) +4.26 (+2.85 to +5.68)
 Crossover 44 −1.48 (−2.31 to −0.64) Ref +1.43 (+0.75 to +2.12) +2.79 (+1.67 to +3.92) +4.05 (+2.80 to +5.30) +5.22 (+4.05 to +6.39)
 Crossover without washout 41 −1.25 (−2.12 to −0.38) Ref +1.27 (+0.56 to +1.97) +2.56 (+1.41 to +3.71) +3.89 (+2.61 to +5.16) +5.24 (+4.01 to +6.48)
By sex
 Men 11 −0.21 (−2.24 to +1.82) Ref +0.55 (−1.02 to +2.12) +1.95 (−0.25 to +4.15) +4.21 (+1.46 to +6.96) +7.03 (+2.60 to +11.47)
 Women 5 −2.68 (−6.54 to +1.17) Ref +2.31 (+0.88 to +3.75) +4.24 (+2.44 to +6.03) +6.15 (+2.81 to +9.50) +8.07 (+2.97 to +13.18)
Participants without hypertension by type of intervention
 Supplementation 11 −0.47 (−0.93 to 0.00) Ref +0.45 (+0.12 to +0.79) +0.88 (+0.34 to +1.42) +1.27 (+0.19 to +2.34) +1.64 (−0.29 to +3.57)
 Diet 4 −0.79 (−1.33 to −0.25) Ref +0.79 (+0.25 to +1.33) +1.59 (+0.51 to +2.67) +2.26 (+0.81 to +3.70) +2.66 (+0.99 to +4.34)
Participants with hypertension by type of intervention
 Supplementation 36 −1.33 (−2.24 to −0.41) Ref +1.32 (+0.54 to +2.10) +2.62 (+1.33 to +3.92) +3.90 (+2.43 to +5.38) +5.17 (+3.60 to +6.73)
 Diet 33 −1.81 (−2.96 to −0.66) Ref +1.76 (+0.76 to +2.75) +3.40 (+1.75 to +5.05) +4.88 (+3.05 to +6.70) +6.19 (+4.51 to +7.86)
Participants with hypertension by medication
   Not taking antihypertensive 
medication
36 −1.35 (−2.38 to −0.31) Ref +1.32 (+0.47 to +2.17) +2.58 (+1.21 to +3.96) +3.78 (+2.32 to +5.23) +4.90 (+3.69 to +6.11)
   Taking antihypertensive medi-
cation
33 −1.91 (−2.96 to −0.86) Ref +1.87 (+0.93 to +2.82) +3.65 (+2.04 to +5.26) +5.28 (+3.38 to +7.17) +6.77 (+4.77 to +8.77)
Participants with hypertension not taking antihypertensive medication by type of intervention
 Supplementation 24 −1.06 (−2.31 to +0.18) Ref +1.10 (+0.06 to +2.14) +2.27 (+0.57 to +3.98) +3.56 (+1.67 to +5.45) +4.95 (+3.03 to +6.86)
 Diet 13 −2.04 (−3.62 to −0.47) Ref +1.92 (+0.56 to +3.28) +3.56 (+1.36 to +5.75) +4.76 (+2.49 to +7.02) +5.60 (+3.83 to +7.38)
Participants with hypertension taking antihypertensive medication by type of intervention
 Supplementation 12 −1.64 (−3.01 to −0.27) Ref +1.62 (+0.38 to +2.86) +3.18 (+1.09 to +5.26) +4.63 (+2.19 to +7.08) +6.01 (+3.28 to +8.74)
 Diet 22 −1.94 (−3.50 to −0.38) Ref +1.93 (+0.50 to +3.36) +3.82 (+1.35 to +6.38) +5.64 (+2.73 to +8.55) +7.41 (+4.42 to +10.40)
Participants with hypertension by baseline systolic blood pressure
 <140 mm Hg 18 −2.14 (−3.64 to −0.64) Ref +2.02 (+0.79 to +3.25) +3.79 (+1.88 to +5.71) +5.22 (+3.19 to +7.25) +6.43 (+4.20 to +8.67)
 ≥140 mm Hg 50 −1.39 (−2.18 to −0.60) Ref +1.38 (+0.68 to +2.09) +2.74 (+1.56 to +3.92) +4.06 (+2.74 to +5.39) +5.35 (+4.10 to +6.60)
Participants with hypertension by baseline systolic blood pressure not taking antihypertensive medication
 <140 mm Hg 6 −2.41 (−3.50 to −1.33) Ref +2.41 (+1.33 to +3.50) +4.66 (+2.63 to +6.69) +5.29 (+3.58 to +6.94) +5.57 (+3.98 to +7.15)
 ≥140 mm Hg 30 −1.22 (−2.29 to −0.15) Ref +1.22 (+0.32 to +2.12) +2.43 (+0.96 to +3.91) +3.65 (+2.07 to +5.24) +4.86 (+3.50 to +6.23)
All participants stratified by baseline sodium levels
 <2.5 g/<109 mmol per day 17 −1.32 (−2.39 to −0.24) Ref +1.21 (+0.37 to +2.05) +2.20 (+0.93 to +3.48) +2.99 (+1.51 to +4.48) +3.65 (+1.85 to +5.44)
 ≥2.5 g/≥109 mmol per day 69 −1.51 (−2.12 to −0.91) Ref +1.47 (+0.94 to +1.99) +2.83 (+1.96 to +3.70) +4.04 (+3.09 to +5.00) +5.11 (+4.24 to +5.98)
All participants by study duration
 <12 wk 64 −1.41 (−2.05 to −0.78) Ref +1.38 (+0.84 to +1.92) +2.70 (+1.81 to +3.58) +3.91 (+2.93 to +4.89) +5.04 (+4.06 to +6.02)
 ≥12 wk 22 −1.01 (−1.87 to −0.16) Ref +1.01 (+0.27 to +1.76) +2.03 (+0.77 to +3.29) +3.05 (+1.54 to +4.55) +4.07 (+2.27 to +5.86)
By hypertension status
 No hypertension
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Table 2. Dose–Response Relationship Between Achieved Sodium Excretion and Systolic Blood Pressure Table 2. Continued
Participants N
1.5 g/65 mmol per day
2.0 g/87 
mmol per day
2.5 g/109 mmol per day 3.0 g/130 mmol per day 3.5 g/152 mmol per day 4.0 g/174 mmol per day
Mean difference (95% CI) Mean difference (95% CI) Mean difference (95% CI) Mean difference (95% CI) Mean difference (95% CI)
All 85 −1.28 (−1.77 to −0.79) Ref +1.26 (+0.84 to +1.69) +2.49 (+1.79 to +3.20) +3.66 (+2.84 to +4.48) +4.79 (+3.89 to +5.69)
By type of intervention
 Supplementation 45 −0.86 (−1.46 to −0.26) Ref +0.89 (+0.39 to +1.38) +1.84 (+1.04 to +2.64) +2.87 (+1.92 to +3.82) +3.97 (+2.72 to +5.22)
 Diet 42 −1.64 (−2.41 to −0.87) Ref +1.60 (+0.92 to +2.28) +3.11 (+1.95 to +4.26) +4.46 (+3.11 to +5.82) +5.69 (+4.28 to +7.09)
By hypertension status
 No hypertension 15 −0.50 (−0.87 to −0.12) Ref +0.50 (+0.19 to +0.80) +1.00 (+0.50 to +1.49) +1.49 (+0.81 to +2.18) +1.99 (+0.92 to +3.06)
 Hypertension 67 −1.58 (−2.30 to −0.86) Ref +1.54 (+0.92 to +2.16) +3.01 (+1.99 to +4.02) +4.35 (+3.23 to +5.47) +5.60 (+4.53 to +6.67)
By study design
 Parallel 42 −1.27 (−1.94 to −0.59) Ref +1.23 (+0.63 to +1.83) +2.37 (+1.36 to +3.39) +3.38 (+2.17 to +4.59) +4.26 (+2.85 to +5.68)
 Crossover 44 −1.48 (−2.31 to −0.64) Ref +1.43 (+0.75 to +2.12) +2.79 (+1.67 to +3.92) +4.05 (+2.80 to +5.30) +5.22 (+4.05 to +6.39)
 Crossover without washout 41 −1.25 (−2.12 to −0.38) Ref +1.27 (+0.56 to +1.97) +2.56 (+1.41 to +3.71) +3.89 (+2.61 to +5.16) +5.24 (+4.01 to +6.48)
By sex
 Men 11 −0.21 (−2.24 to +1.82) Ref +0.55 (−1.02 to +2.12) +1.95 (−0.25 to +4.15) +4.21 (+1.46 to +6.96) +7.03 (+2.60 to +11.47)
 Women 5 −2.68 (−6.54 to +1.17) Ref +2.31 (+0.88 to +3.75) +4.24 (+2.44 to +6.03) +6.15 (+2.81 to +9.50) +8.07 (+2.97 to +13.18)
Participants without hypertension by type of intervention
 Supplementation 11 −0.47 (−0.93 to 0.00) Ref +0.45 (+0.12 to +0.79) +0.88 (+0.34 to +1.42) +1.27 (+0.19 to +2.34) +1.64 (−0.29 to +3.57)
 Diet 4 −0.79 (−1.33 to −0.25) Ref +0.79 (+0.25 to +1.33) +1.59 (+0.51 to +2.67) +2.26 (+0.81 to +3.70) +2.66 (+0.99 to +4.34)
Participants with hypertension by type of intervention
 Supplementation 36 −1.33 (−2.24 to −0.41) Ref +1.32 (+0.54 to +2.10) +2.62 (+1.33 to +3.92) +3.90 (+2.43 to +5.38) +5.17 (+3.60 to +6.73)
 Diet 33 −1.81 (−2.96 to −0.66) Ref +1.76 (+0.76 to +2.75) +3.40 (+1.75 to +5.05) +4.88 (+3.05 to +6.70) +6.19 (+4.51 to +7.86)
Participants with hypertension by medication
   Not taking antihypertensive 
medication
36 −1.35 (−2.38 to −0.31) Ref +1.32 (+0.47 to +2.17) +2.58 (+1.21 to +3.96) +3.78 (+2.32 to +5.23) +4.90 (+3.69 to +6.11)
   Taking antihypertensive medi-
cation
33 −1.91 (−2.96 to −0.86) Ref +1.87 (+0.93 to +2.82) +3.65 (+2.04 to +5.26) +5.28 (+3.38 to +7.17) +6.77 (+4.77 to +8.77)
Participants with hypertension not taking antihypertensive medication by type of intervention
 Supplementation 24 −1.06 (−2.31 to +0.18) Ref +1.10 (+0.06 to +2.14) +2.27 (+0.57 to +3.98) +3.56 (+1.67 to +5.45) +4.95 (+3.03 to +6.86)
 Diet 13 −2.04 (−3.62 to −0.47) Ref +1.92 (+0.56 to +3.28) +3.56 (+1.36 to +5.75) +4.76 (+2.49 to +7.02) +5.60 (+3.83 to +7.38)
Participants with hypertension taking antihypertensive medication by type of intervention
 Supplementation 12 −1.64 (−3.01 to −0.27) Ref +1.62 (+0.38 to +2.86) +3.18 (+1.09 to +5.26) +4.63 (+2.19 to +7.08) +6.01 (+3.28 to +8.74)
 Diet 22 −1.94 (−3.50 to −0.38) Ref +1.93 (+0.50 to +3.36) +3.82 (+1.35 to +6.38) +5.64 (+2.73 to +8.55) +7.41 (+4.42 to +10.40)
Participants with hypertension by baseline systolic blood pressure
 <140 mm Hg 18 −2.14 (−3.64 to −0.64) Ref +2.02 (+0.79 to +3.25) +3.79 (+1.88 to +5.71) +5.22 (+3.19 to +7.25) +6.43 (+4.20 to +8.67)
 ≥140 mm Hg 50 −1.39 (−2.18 to −0.60) Ref +1.38 (+0.68 to +2.09) +2.74 (+1.56 to +3.92) +4.06 (+2.74 to +5.39) +5.35 (+4.10 to +6.60)
Participants with hypertension by baseline systolic blood pressure not taking antihypertensive medication
 <140 mm Hg 6 −2.41 (−3.50 to −1.33) Ref +2.41 (+1.33 to +3.50) +4.66 (+2.63 to +6.69) +5.29 (+3.58 to +6.94) +5.57 (+3.98 to +7.15)
 ≥140 mm Hg 30 −1.22 (−2.29 to −0.15) Ref +1.22 (+0.32 to +2.12) +2.43 (+0.96 to +3.91) +3.65 (+2.07 to +5.24) +4.86 (+3.50 to +6.23)
All participants stratified by baseline sodium levels
 <2.5 g/<109 mmol per day 17 −1.32 (−2.39 to −0.24) Ref +1.21 (+0.37 to +2.05) +2.20 (+0.93 to +3.48) +2.99 (+1.51 to +4.48) +3.65 (+1.85 to +5.44)
 ≥2.5 g/≥109 mmol per day 69 −1.51 (−2.12 to −0.91) Ref +1.47 (+0.94 to +1.99) +2.83 (+1.96 to +3.70) +4.04 (+3.09 to +5.00) +5.11 (+4.24 to +5.98)
All participants by study duration
 <12 wk 64 −1.41 (−2.05 to −0.78) Ref +1.38 (+0.84 to +1.92) +2.70 (+1.81 to +3.58) +3.91 (+2.93 to +4.89) +5.04 (+4.06 to +6.02)
 ≥12 wk 22 −1.01 (−1.87 to −0.16) Ref +1.01 (+0.27 to +1.76) +2.03 (+0.77 to +3.29) +3.05 (+1.54 to +4.55) +4.07 (+2.27 to +5.86)
By hypertension status
 No hypertension
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results compared with the longer studies, apart from a 
lack of effect on DBP at very low exposure levels, ie, <2 
g/d (Figure VII in the Data Supplement).
A stratified analysis based on study design (paral-
lel versus crossover) showed a steeper dose–response 
curve in crossover studies for SBP and DBP at high lev-
els of urinary sodium excretion, with a similar pattern 
in crossover studies overall considered compared with 
those without a washout period (the large majority of 
them; Figure VIII in the Data Supplement). Conversely, 
<2 g/d of sodium intake crossover trials, in contrast 
with parallel designs, failed to document a reduction in 
DBP at low levels of urinary sodium excretion. Subgroup 
analysis in men and women did not show evidence of 
sex-related differences except for a slightly steeper as-
sociation in women, although these estimates were sta-
tistically imprecise, being based on only 16 studies (11 
in men and 5 in women; Figure IX in the Data Supple-
ment). No age-related difference emerged after restric-
tion of the analysis to participants ≤55 years of age, the 
only age subgroup for which we could compute a pat-
tern because in most studies participants had a mixed 
age and no age-specific estimates were reported.
We also assessed the effect of the difference in uri-
nary sodium excretion attributable to the intervention 
and control treatments on BP, independent of baseline 
sodium consumption. We found that a larger difference 
in sodium intake was associated with a larger effect on 
both SBP and DBP, with an approximately linear posi-
tive association (Figure 5). Similarly to the analysis on 
achieved sodium intake reported in Figure 2, when we 
stratified the analysis according to the methodology 
used to achieve the changes in sodium intake across 
trial arms, we found that the dietary changes were 
much more effective in producing BP changes com-
pared with sodium supplementation alone. The nearly 
linear association between sodium difference between 
the treatment arms and BP changes found in the over-
all analysis also emerged in an analysis that stratified 
for baseline presence or absence of hypertension, al-
beit with a much steeper dose–response curve in the 
participants with hypertension (Figure 6). Likewise, the 
pattern was seen in trials of shorter and longer duration 
(Figure X in the Data Supplement).
Taking into account the risk of bias of the included 
studies, we reran the main analyses after removing 
the 2 studies at high risk, with little effect on the re-
sults, even after limiting the analysis to trials based 
on dietary modifications, which was the intervention 
modality in the 2 excluded studies (Figure XI in the 
Data Supplement). Funnel plot analyses suggested 
moderate small-study effects for SBP and moderate 
to substantial effects for DBP considering all stud-
ies (Figure XII in the Data Supplement), as confirmed 
by the trim-and-fill analysis (Figure XIII in the Data 
Supplement). Stratified analysis by type of interven-
tion and hypertension status provided some evidence 
that small-study bias may have occurred in the dietary 
studies (Figures XIV and XV in the Data Supplement) 
and in those carried out in participants with hyperten-
sion (Figures XVI and XVII in the Data Supplement).
DISCUSSION
We conducted a dose–response meta-analysis of clini-
cal trials that had investigated the effects of sodium re-
duction on level of BP. Our review was not conducted 
because of uncertainty regarding whether a reduction 
in sodium intake lowers BP, for which consistent evi-
dence has been accumulated over decades.1,4,7 Instead, 
our endeavor was prompted by a desire to determine 
whether the dose–response relationship between 
changes in sodium intake and BP is linear or curvilin-
ear, to identify any thresholds for the relationship, and 
  ≥12 wk 4 −0.79 (−1.33 to −0.25) Ref +0.79 (+0.25 to +1.33) +1.59 (+0.51 to +2.67) +2.26 (+0.81 to +3.70) +2.66 (+0.99 to +4.34)
 Hypertension
  <12 wk 53 −1.66 (−2.48 to −0.84) Ref +1.62 (+0.90 to +2.33) +3.13 (+1.94 to +4.32) +4.50 (+3.18 to +5.82) +5.72 (+4.50 to +6.95)
  ≥12 wk 15 −1.20 (−2.85 to +0.46) Ref +1.27 (−0.04 to +2.58) +2.71 (+0.89 to +4.53) +4.41 (+2.67 to +6.15) +6.25 (+3.44 to +9.07)
By type of intervention
 Supplementation
  <12 wk 43 −0.97 (−1.60 to −0.34) Ref +0.98 (+0.44 to +1.51) +1.98 (+1.10 to +2.85) +3.00 (+1.97 to +4.03) +4.05 (+2.77 to +5.33)
  ≥12 wk 2 —  — —  —  —  —  
 Diet
  <12 wk 22 −1.91 (−3.32 to −0.49) Ref +1.79 (+0.61 to +2.98) +3.39 (+1.44 to +5.35) +4.72 (+2.55 to +6.89) +5.79 (+3.88 to +7.70)
  ≥12 wk 20 −1.22 (−2.13 to −0.31) Ref +1.21 (+0.34 to +2.08) +2.37 (+0.86 to +3.87) +3.43 (+1.63 to +5.22) +4.40 (+2.37 to +6.42)
(Continued ) Estimates of mean difference and 95% CI from spline regression analysis, with number (N) of studies in each analysis.
Table 2. Continued Table 2. Continued
Participants N
1.5 g/65 mmol per day
2.0 g/87 
mmol per day 2.5 g/109 mmol per day 3.0 g/130 mmol per day 3.5 g/152 mmol per day 4.0 g/174 mmol per day
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ARTICLE  ≥12 wk 4 −0.79 (−1.33 to −0.25) Ref +0.79 (+0.25 to +1.33) +1.59 (+0.51 to +2.67) +2.26 (+0.81 to +3.70) +2.66 (+0.99 to +4.34)
 Hypertension
  <12 wk 53 −1.66 (−2.48 to −0.84) Ref +1.62 (+0.90 to +2.33) +3.13 (+1.94 to +4.32) +4.50 (+3.18 to +5.82) +5.72 (+4.50 to +6.95)
  ≥12 wk 15 −1.20 (−2.85 to +0.46) Ref +1.27 (−0.04 to +2.58) +2.71 (+0.89 to +4.53) +4.41 (+2.67 to +6.15) +6.25 (+3.44 to +9.07)
By type of intervention
 Supplementation
  <12 wk 43 −0.97 (−1.60 to −0.34) Ref +0.98 (+0.44 to +1.51) +1.98 (+1.10 to +2.85) +3.00 (+1.97 to +4.03) +4.05 (+2.77 to +5.33)
  ≥12 wk 2 —  — —  —  —  —  
 Diet
  <12 wk 22 −1.91 (−3.32 to −0.49) Ref +1.79 (+0.61 to +2.98) +3.39 (+1.44 to +5.35) +4.72 (+2.55 to +6.89) +5.79 (+3.88 to +7.70)
  ≥12 wk 20 −1.22 (−2.13 to −0.31) Ref +1.21 (+0.34 to +2.08) +2.37 (+0.86 to +3.87) +3.43 (+1.63 to +5.22) +4.40 (+2.37 to +6.42)
(Continued ) Estimates of mean difference and 95% CI from spline regression analysis, with number (N) of studies in each analysis.
Table 2. Continued Table 2. Continued
Participants N
1.5 g/65 mmol per day
2.0 g/87 
mmol per day 2.5 g/109 mmol per day 3.0 g/130 mmol per day 3.5 g/152 mmol per day 4.0 g/174 mmol per day
Mean difference (95% CI) Mean difference (95% CI) Mean difference (95% CI) Mean difference (95% CI) Mean difference (95% CI)
to specifically assess the relationship in the group for 
whom the sodium–BP association has been most chal-
lenged, ie, in adults without hypertension.3,21 We were 
also influenced by our recent indication of a U-shaped 
dose–response relationship between potassium in-
take and BP, previously undetected using traditional 
meta-analyses that use forest plots or linear models.119 
Many systematic reviews and meta-analyses have at-
tempted to assess the sodium–BP relationship in ex-
perimental studies, including 2 recent reports,3,4 but 
they have been unable to fully characterize it because 
they have used linear models or stratified the exposure 
by category of sodium reduction between intervention 
and control arms in each study, or at baseline, thus 
being unable to smoothly shape the relationship be-
tween sodium intake and BP over the entire range of 
exposure. These recent meta-analyses included a less 
comprehensive literature database compared with the 
one we used, and this also resulted in greater statisti-
cal precision for the effect estimates we computed, 
including those for participants without hypertension, 
the subgroup characterized by the lowest number of 
available studies.
Our statistical approach differs from previous meta-
analyses.10,19 Mozaffarian et al10 reported 2 spline re-
gression analyses of trials of any duration or of at least 
1-week duration, based on the literature considered 
in 2011 and 2013 Cochrane meta-analyses.7,120 The 
2019 National Academies of Sciences, Engineering, 
and Medicine Dietary Reference Intakes Committee re-
ported a meta-analysis based on trials lasting at least 
4 weeks.19 These 2 meta-analyses, however, only as-
sessed change in SBP for differences in sodium intake 
between the study arms, also assuming a single com-
mon dose–response relationship underlying multiple 
studies, as implied by the use of a fixed-effects model. 
A recent meta-analysis by Huang et al4 also attempted 
to characterize the dose–response relationship between 
sodium exposure and BP. In that review, contrasts across 
studies in each quantile of the dose were combined 
by computing multiple models. Our 1-stage modeling 
allowed us to preserve the study-specific structure of 
contrasts in the estimation of the dose–response rela-
tionship within a single model. Huang et al4 also had 
to categorize sodium exposure dose according to data-
dependent quantiles, whereas we could flexibly model 
the dose as a quantitative variable, fitting a single dose–
response random-effects model that takes into account 
heterogeneity across the studies. We considered the 
effect of achieved level of sodium intake at the end of 
the trial on BP in addition to the effect of the difference 
in sodium excretion between the treatment arms, thus 
making the results more applicable to risk assessment 
in clinical practice and public health.
Overall, we found only small departures from lin-
earity for the association between sodium intake and 
BP lowering across the entire range of exposure tested 
and achieved in the trials. This was confirmed by the 
analyses based on difference in sodium intake be-
tween intervention and control arms. Dietary sodium 
reduction was accompanied by an approximately lin-
ear decrease in SBP and by a somewhat less steep but 
still nearly linear decrease in DBP. The SBP reduction of 
5.4 mm Hg associated with a 100 mmol/d decrease in 
achieved sodium intake that we report is similar to a 
previous finding of 5.8 mm Hg by He et al,7 although 
our results were much more statistically stable (95% 
CI, 4.4–6.5 versus 2.5–9.2, respectively). A decrease in 
achieved sodium intake <2 g/d was accompanied by 
a considerably larger decrease in SBP compared with 
DBP. This difference was slightly more apparent when 
we limited the analysis to trials based on initial sodium 
restriction followed by behavior change interventions 
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Table 3. Dose–Response Relationship Between Achieved Sodium Excretion and Diastolic Blood Pressure Table 3. Continued
Participants N
1.5 g/65 mmol per day
2.0 g/87 mmol 
per day
2.5 g/109 mmol per day 3.0 g/130 mmol per day 3.5 g/152 mmol per day 4.0 g/174 mmol per day
Mean difference (95% CI) Mean difference (95% CI) Mean difference (95% CI) Mean difference (95% CI) Mean difference (95% CI)
All 85 −0.36 (−0.66 to −0.07) Ref +0.39 (+0.14 to +0.65) +0.85 (+0.43 to +1.26) +1.39 (+0.90 to +1.88) +2.02 (+1.44 to +2.59)
By type of intervention
 Supplementation 45 −0.19 (−0.64 to +0.27) Ref +0.25 (−0.13 to +0.63) +0.64 (+0.05 to +1.23) +1.22 (+0.57 to +1.87) +1.95 (+1.16 to +2.74)
 Diet 42 −0.67 (−1.15 to −0.19) Ref +0.66 (+0.24 to +1.08) +1.29 (+0.58 to +2.01) +1.89 (+1.06 to +2.72) +2.45 (+1.57 to +3.33)
By hypertension status
 No hypertension 15 −0.21 (−0.70 to +0.28) Ref +0.21 (−0.20 to +0.62) +0.41 (−0.24 to +1.07) +0.62 (−0.13 to +1.38) +0.83 (−0.06 to +1.72)
 Hypertension 67 −0.67 (−1.12 to −0.23) Ref +0.67 (+0.29 to +1.05) +1.33 (+0.72 to +1.95) +1.98 (+1.32 to +2.64) +2.62 (+2.00 to +3.23)
By study design
 Parallel 42 −0.63 (−1.07 to −0.19) Ref +0.62 (+0.24 to +1.00) +1.19 (+0.58 to +1.81) +1.70 (+1.01 to +2.41) +2.18 (+1.33 to +3.03)
 Crossover 44 −0.11 (−0.54 to +0.31) Ref +0.20 (−0.14 to +0.55) +0.56 (−0.01 to +1.13) +1.12 (+0.47 to +1.78) +1.87 (+1.15 to +2.59)
 Crossover without washout 41 −0.03 (−0.45 to +0.39) Ref +0.14 (−0.20 to +0.48) +0.46 (−0.10 to +1.01) +1.02 (+0.37 to +1.66) +1.77 (+1.03 to +2.51)
By sex
 Men 11 −0.60 (−1.60 to +0.40) Ref +0.64 (−0.17 to +1.44) +1.36 (+0.20 to +2.52) +2.18 (+0.95 to +3.41) +3.06 (+1.58 to +4.54)
 Women 5 −0.77 (−3.19 to +1.66) Ref +1.00 (+0.09 to +1.90) +2.24 (+1.10 to +3.38) +3.48 (+1.36 to +5.60) +4.72 (+1.50 to +7.95)
Participants without hypertension by type of intervention
 Supplementation 11 +0.11 (−0.63 to +0.86) Ref 0.00 (−0.54 to +0.54) +0.26 (−0.47 to +0.98) +0.80 (−0.30 to +1.91) +1.48 (−0.53 to +3.49)
 Diet 4 −0.39 (−0.77 to −0.01) Ref +0.39 (+0.01 to +0.77) +0.78 (+0.02 to +1.53) +1.07 (+0.07 to +2.07) +1.16 (+0.07 to +2.26)
Participants with hypertension by type of intervention
 Supplementation 36 −0.37 (−1.00 to +0.26) Ref +0.42 (−0.11 to +0.95) +0.96 (+0.10 to +1.82) +1.67 (+0.74 to +2.59) +2.52 (+1.61 to +3.43)
 Diet 33 −0.95 (−1.52 to −0.39) Ref +0.92 (+0.44 to +1.41) +1.77 (+0.97 to +2.57) +2.51 (+1.63 to +3.40) +3.15 (+2.29 to +4.01)
Participants with hypertension by medication
   Not taking antihypertensive 
medication
36 −0.67 (−1.38 to +0.04) Ref +0.67 (+0.08 to +1.25) +1.32 (+0.38 to +2.25) +1.96 (+0.98 to +2.94) +2.58 (+1.78 to +3.37)
   Taking antihypertensive 
medication
33 −0.72 (−1.25 to −0.18) Ref +0.72 (+0.24 to +1.20) +1.45 (+0.64 to +2.25) +2.20 (+1.26 to +3.13) +2.96 (+1.94 to +3.97)
Participants with hypertension not taking antihypertensive medication by type of intervention
 Supplementation 24 −0.20 (−1.02 to +0.63) Ref +0.28 (−0.41 to +0.96) +0.72 (−0.39 to +1.82) +1.39 (+0.22 to +2.56) +2.29 (+1.21 to +3.37)
 Diet 13 −1.62 (−2.73 to −0.52) Ref +1.48 (+0.53 to +2.43) +2.62 (+1.09 to +4.16) +3.26 (+1.68 to +4.84) +3.49 (+2.26 to +4.72)
Participants with hypertension taking antihypertensive medication by type of intervention
 Supplementation 12 −0.66 (−1.53 to +0.21) Ref +0.68 (−0.09 to +1.46) +1.43 (+0.15 to +2.71) +2.28 (+0.81 to +3.75) +3.21 (+1.51 to +4.91)
 Diet 22 −0.95 (−1.63 to −0.27) Ref +0.93 (+0.32 to +1.55) +1.81 (+0.77 to +2.84) +2.57 (+1.39 to +3.75) +3.24 (+1.97 to +4.52)
Participants with hypertension by baseline systolic blood pressure
 <140 mm Hg 18 −0.64 (−1.48 to +0.20) Ref +0.67 (0.00 to +1.35) +1.42 (+0.40 to +2.44) +2.26 (+1.13 to +3.38) +3.16 (+1.69 to +4.62)
 ≥140 mm Hg 50 −0.66 (−1.15 to −0.18) Ref +0.66 (+0.23 to +1.09) +1.31 (+0.60 to +2.02) +1.95 (+1.18 to +2.72) +2.58 (+1.89 to +3.26)
Participants with hypertension by baseline systolic blood pressure not taking antihypertensive medication
 <140 mm Hg 6 −1.28 (−2.20 to −0.35) Ref +1.28 (+0.35 to +2.20) +2.46 (+0.74 to +4.19) +2.76 (+1.35 to +4.18) +2.91 (+1.66 to +4.15)
 ≥140 mm Hg 30 −0.59 (−1.32 to +0.13) Ref +0.61 (0.00 to +1.21) +1.25 (+0.26 to +2.22) +1.92 (+0.88 to +2.95) +2.63 (+1.76 to +3.50)
All participants stratified by baseline sodium levels
 <2.5 g/<109 mmol per day 17 −0.35 (−0.98 to +0.28) Ref +0.32 (−0.18 to +0.83) +0.60 (−0.23 to +1.43) +0.83 (−0.29 to +1.94) +1.02 (−0.50 to +2.55)
 ≥2.5 g/≥109 mmol per day 69 −0.55 (−0.91 to −0.20) Ref +0.56 (+0.26 to +0.87) +1.14 (+0.64 to +1.65) +1.75 (+1.19 to +2.32) +2.39 (+1.80 to +2.98)
All participants by study duration
 <12 wk 64 −0.26 (−0.59 to +0.07) Ref +0.31 (+0.03 to +0.59) +0.73 (+0.27 to +1.19) +1.31 (+0.77 to +1.84) +2.02 (+1.38 to +2.66)
 ≥12 wk 22 −0.70 (−1.30 to −0.11) Ref +0.67 (+0.14 to +1.20) +1.25 (+0.37 to +2.14) +1.71 (+0.67 to +2.75) +2.04 (+0.86 to +3.23)
By hypertension status
 No hypertension
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Table 3. Dose–Response Relationship Between Achieved Sodium Excretion and Diastolic Blood Pressure Table 3. Continued
Participants N
1.5 g/65 mmol per day
2.0 g/87 mmol 
per day
2.5 g/109 mmol per day 3.0 g/130 mmol per day 3.5 g/152 mmol per day 4.0 g/174 mmol per day
Mean difference (95% CI) Mean difference (95% CI) Mean difference (95% CI) Mean difference (95% CI) Mean difference (95% CI)
All 85 −0.36 (−0.66 to −0.07) Ref +0.39 (+0.14 to +0.65) +0.85 (+0.43 to +1.26) +1.39 (+0.90 to +1.88) +2.02 (+1.44 to +2.59)
By type of intervention
 Supplementation 45 −0.19 (−0.64 to +0.27) Ref +0.25 (−0.13 to +0.63) +0.64 (+0.05 to +1.23) +1.22 (+0.57 to +1.87) +1.95 (+1.16 to +2.74)
 Diet 42 −0.67 (−1.15 to −0.19) Ref +0.66 (+0.24 to +1.08) +1.29 (+0.58 to +2.01) +1.89 (+1.06 to +2.72) +2.45 (+1.57 to +3.33)
By hypertension status
 No hypertension 15 −0.21 (−0.70 to +0.28) Ref +0.21 (−0.20 to +0.62) +0.41 (−0.24 to +1.07) +0.62 (−0.13 to +1.38) +0.83 (−0.06 to +1.72)
 Hypertension 67 −0.67 (−1.12 to −0.23) Ref +0.67 (+0.29 to +1.05) +1.33 (+0.72 to +1.95) +1.98 (+1.32 to +2.64) +2.62 (+2.00 to +3.23)
By study design
 Parallel 42 −0.63 (−1.07 to −0.19) Ref +0.62 (+0.24 to +1.00) +1.19 (+0.58 to +1.81) +1.70 (+1.01 to +2.41) +2.18 (+1.33 to +3.03)
 Crossover 44 −0.11 (−0.54 to +0.31) Ref +0.20 (−0.14 to +0.55) +0.56 (−0.01 to +1.13) +1.12 (+0.47 to +1.78) +1.87 (+1.15 to +2.59)
 Crossover without washout 41 −0.03 (−0.45 to +0.39) Ref +0.14 (−0.20 to +0.48) +0.46 (−0.10 to +1.01) +1.02 (+0.37 to +1.66) +1.77 (+1.03 to +2.51)
By sex
 Men 11 −0.60 (−1.60 to +0.40) Ref +0.64 (−0.17 to +1.44) +1.36 (+0.20 to +2.52) +2.18 (+0.95 to +3.41) +3.06 (+1.58 to +4.54)
 Women 5 −0.77 (−3.19 to +1.66) Ref +1.00 (+0.09 to +1.90) +2.24 (+1.10 to +3.38) +3.48 (+1.36 to +5.60) +4.72 (+1.50 to +7.95)
Participants without hypertension by type of intervention
 Supplementation 11 +0.11 (−0.63 to +0.86) Ref 0.00 (−0.54 to +0.54) +0.26 (−0.47 to +0.98) +0.80 (−0.30 to +1.91) +1.48 (−0.53 to +3.49)
 Diet 4 −0.39 (−0.77 to −0.01) Ref +0.39 (+0.01 to +0.77) +0.78 (+0.02 to +1.53) +1.07 (+0.07 to +2.07) +1.16 (+0.07 to +2.26)
Participants with hypertension by type of intervention
 Supplementation 36 −0.37 (−1.00 to +0.26) Ref +0.42 (−0.11 to +0.95) +0.96 (+0.10 to +1.82) +1.67 (+0.74 to +2.59) +2.52 (+1.61 to +3.43)
 Diet 33 −0.95 (−1.52 to −0.39) Ref +0.92 (+0.44 to +1.41) +1.77 (+0.97 to +2.57) +2.51 (+1.63 to +3.40) +3.15 (+2.29 to +4.01)
Participants with hypertension by medication
   Not taking antihypertensive 
medication
36 −0.67 (−1.38 to +0.04) Ref +0.67 (+0.08 to +1.25) +1.32 (+0.38 to +2.25) +1.96 (+0.98 to +2.94) +2.58 (+1.78 to +3.37)
   Taking antihypertensive 
medication
33 −0.72 (−1.25 to −0.18) Ref +0.72 (+0.24 to +1.20) +1.45 (+0.64 to +2.25) +2.20 (+1.26 to +3.13) +2.96 (+1.94 to +3.97)
Participants with hypertension not taking antihypertensive medication by type of intervention
 Supplementation 24 −0.20 (−1.02 to +0.63) Ref +0.28 (−0.41 to +0.96) +0.72 (−0.39 to +1.82) +1.39 (+0.22 to +2.56) +2.29 (+1.21 to +3.37)
 Diet 13 −1.62 (−2.73 to −0.52) Ref +1.48 (+0.53 to +2.43) +2.62 (+1.09 to +4.16) +3.26 (+1.68 to +4.84) +3.49 (+2.26 to +4.72)
Participants with hypertension taking antihypertensive medication by type of intervention
 Supplementation 12 −0.66 (−1.53 to +0.21) Ref +0.68 (−0.09 to +1.46) +1.43 (+0.15 to +2.71) +2.28 (+0.81 to +3.75) +3.21 (+1.51 to +4.91)
 Diet 22 −0.95 (−1.63 to −0.27) Ref +0.93 (+0.32 to +1.55) +1.81 (+0.77 to +2.84) +2.57 (+1.39 to +3.75) +3.24 (+1.97 to +4.52)
Participants with hypertension by baseline systolic blood pressure
 <140 mm Hg 18 −0.64 (−1.48 to +0.20) Ref +0.67 (0.00 to +1.35) +1.42 (+0.40 to +2.44) +2.26 (+1.13 to +3.38) +3.16 (+1.69 to +4.62)
 ≥140 mm Hg 50 −0.66 (−1.15 to −0.18) Ref +0.66 (+0.23 to +1.09) +1.31 (+0.60 to +2.02) +1.95 (+1.18 to +2.72) +2.58 (+1.89 to +3.26)
Participants with hypertension by baseline systolic blood pressure not taking antihypertensive medication
 <140 mm Hg 6 −1.28 (−2.20 to −0.35) Ref +1.28 (+0.35 to +2.20) +2.46 (+0.74 to +4.19) +2.76 (+1.35 to +4.18) +2.91 (+1.66 to +4.15)
 ≥140 mm Hg 30 −0.59 (−1.32 to +0.13) Ref +0.61 (0.00 to +1.21) +1.25 (+0.26 to +2.22) +1.92 (+0.88 to +2.95) +2.63 (+1.76 to +3.50)
All participants stratified by baseline sodium levels
 <2.5 g/<109 mmol per day 17 −0.35 (−0.98 to +0.28) Ref +0.32 (−0.18 to +0.83) +0.60 (−0.23 to +1.43) +0.83 (−0.29 to +1.94) +1.02 (−0.50 to +2.55)
 ≥2.5 g/≥109 mmol per day 69 −0.55 (−0.91 to −0.20) Ref +0.56 (+0.26 to +0.87) +1.14 (+0.64 to +1.65) +1.75 (+1.19 to +2.32) +2.39 (+1.80 to +2.98)
All participants by study duration
 <12 wk 64 −0.26 (−0.59 to +0.07) Ref +0.31 (+0.03 to +0.59) +0.73 (+0.27 to +1.19) +1.31 (+0.77 to +1.84) +2.02 (+1.38 to +2.66)
 ≥12 wk 22 −0.70 (−1.30 to −0.11) Ref +0.67 (+0.14 to +1.20) +1.25 (+0.37 to +2.14) +1.71 (+0.67 to +2.75) +2.04 (+0.86 to +3.23)
By hypertension status
 No hypertension
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changes in sodium intake caused by other dietary 
changes, compared with studies based on dietary so-
dium reduction on the basis of sodium supplement 
administration. In the analysis that is based on sodium 
supplement administration, the reduction in DBP <2 
g/d of sodium intake was almost null, thus providing 
some support to use of this value as a threshold with 
reference to the effect of sodium reduction on DBP. 
However, there was no suggestion of a threshold for 
the effect of sodium reduction on SBP. Overall, our 
findings suggest that the effect of sodium reduction 
on BP is beneficial across a wide range of intake, sup-
porting recommendations to reduce sodium intake as 
much as possible but in particular to achieve a reduc-
tion that would meet the current dietary recommen-
dations of 2 to 2.3 g/d,19,20 mainly based on the aim to 
reduce BP and the related increased risk of stroke and 
other CVD complications.8,15,121
The aforementioned assessment is based on the 
major strength of the present study: use of a novel 
statistical methodology that allows use of 2-arm com-
parisons to obtain a continuous modeling of the dose–
response relationship between sodium reduction and 
BP while retaining the matched design of trials. This 
method avoids the rigidity of linear functions and the 
pitfalls of forest plot analyses that can result from non-
homogeneous and extreme categories of exposure 
and is particularly helpful for analysis of nonlinear re-
lationships, as recently reported for potassium.119 Our 
confirmation of a linear relationship between sodium 
intake and BP is consistent with the strong positive as-
sociation noted in recent dose–response meta-analyses 
between sodium intake and the risk of stroke, a dis-
ease for which high BP is the leading risk factor.122–124 
This positive dose–response relationship yielded by the 
experimental evidence in humans overall available also 
mirrors what has been already noted in the few single 
RCTs encompassing more than 2 categories of sodium 
intake, though within a narrower range of sodium ex-
posure compared with the whole set of RCTs. A well-
known example is the trial carried out to assess the 
effects of 3 decreasing amounts of sodium restriction 
in participants consuming either a typical US diet or a 
DASH (Dietary Approaches to Stop Hypertension) diet, 
where a clear dose–response relationship between so-
dium exposure and both SBP and DBP was noted.99 
Another study, of much smaller size, encompassed 3 
categories of sodium exposure in normotensive partici-
pants and could not find a dose–response relationship 
with either SBP or DBP.109
A key issue in the controversy regarding the efficacy 
of sodium reduction for BP lowering is the background 
level of BP in those being treated. There is general ac-
ceptance of a beneficial effect in adults with high BP 
but not everyone has accepted the premise that reduc-
tion in dietary sodium is effective for BP reduction in 
adults with lower levels of BP.1,3,125,126 Our meta-anal-
ysis results are consistent with many previous meta-
analysis reports in showing a larger reduction in BP in 
those with a higher starting level of BP but we noted 
a similar pattern of effect, albeit with smaller reduc-
tions in BP, in those with a lower starting level of BP,4,7,8 
contrary to the null effect in some previous reports.2,3,21 
This was particularly true for SBP, a major risk predictor 
for CVD and chronic kidney disease.19,127,128 We found 
little evidence that decreasing sodium intake <2 g/d 
lowered DBP in participants without hypertension, but 
the relevant estimate was imprecise. In participants 
with hypertension, a higher baseline BP level (as cat-
egorized by use of an SBP cut point of 140 mm Hg) was 
associated with a greater capacity of increased sodium 
intake to raise BP, suggesting more adverse effects of 
excessive sodium intake and more evident beneficial 
effects reducing sodium intake for those with more se-
vere hypertension.
  ≥12 wk 4 −0.39 (−0.77 to −0.01) Ref +0.39 (+0.01 to +0.77) +0.78 (+0.02 to +1.53) +1.07 (+0.07 to +2.07) +1.16 (+0.07 to +2.26)
 Hypertension
  <12 wk 53 −0.64 (−1.14 to −0.13) Ref +0.64 (+0.20 to +1.07) +1.27 (+0.56 to +1.99) +1.91 (+1.13 to +2.68) +2.54 (+1.86 to +3.22)
  ≥12 wk 15 −0.83 (−1.91 to +0.25) Ref +0.84 (−0.02 to +1.70) +1.71 (+0.50 to +2.92) +2.61 (+1.43 to +3.80) +3.54 (+1.70 to +5.38)
By type of intervention
 Supplementation
  <12 wk 43 −0.22 (−0.71 to +0.27) Ref +0.28 (−0.13 to +0.69) +0.69 (+0.04 to +1.33) +1.28 (+0.57 to +1.99) +2.02 (+1.21 to +2.83)
  ≥12 wk 2 —  — —  —  —  —  
 Diet             
  <12 wk 22 −0.62 (−1.29 to +0.04) Ref +0.63 (+0.08 to +1.19) +1.28 (+0.35 to +2.21) +1.94 (+0.85 to +3.03) +2.62 (+1.48 to +3.76)
  ≥12 wk 20 −0.76 (−1.39 to −0.12) Ref +0.74 (+0.13 to +1.34) +1.38 (+0.33 to +2.43) +1.84 (+0.60 to +3.08) +2.13 (+0.79 to +3.48)
(Continued ) Estimates of mean difference and 95% CI from spline regression analysis. 
Table 3. Continued Table 3. Continued
Participants N
1.5 g/65 mmol per day
2.0 g/87 mmol 
per day
2.5 g/109 mmol per day 3.0 g/130 mmol per day 3.5 g/152 mmol per day 4.0 g/174 mmol per day
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  ≥12 wk 4 −0.39 (−0.77 to −0.01) Ref +0.39 (+0.01 to +0.77) +0.78 (+0.02 to +1.53) +1.07 (+0.07 to +2.07) +1.16 (+0.07 to +2.26)
 Hypertension
  <12 wk 53 −0.64 (−1.14 to −0.13) Ref +0.64 (+0.20 to +1.07) +1.27 (+0.56 to +1.99) +1.91 (+1.13 to +2.68) +2.54 (+1.86 to +3.22)
  ≥12 wk 15 −0.83 (−1.91 to +0.25) Ref +0.84 (−0.02 to +1.70) +1.71 (+0.50 to +2.92) +2.61 (+1.43 to +3.80) +3.54 (+1.70 to +5.38)
By type of intervention
 Supplementation
  <12 wk 43 −0.22 (−0.71 to +0.27) Ref +0.28 (−0.13 to +0.69) +0.69 (+0.04 to +1.33) +1.28 (+0.57 to +1.99) +2.02 (+1.21 to +2.83)
  ≥12 wk 2 —  — —  —  —  —  
 Diet             
  <12 wk 22 −0.62 (−1.29 to +0.04) Ref +0.63 (+0.08 to +1.19) +1.28 (+0.35 to +2.21) +1.94 (+0.85 to +3.03) +2.62 (+1.48 to +3.76)
  ≥12 wk 20 −0.76 (−1.39 to −0.12) Ref +0.74 (+0.13 to +1.34) +1.38 (+0.33 to +2.43) +1.84 (+0.60 to +3.08) +2.13 (+0.79 to +3.48)
(Continued ) Estimates of mean difference and 95% CI from spline regression analysis. 
Table 3. Continued Table 3. Continued
Participants N
1.5 g/65 mmol per day
2.0 g/87 mmol 
per day
2.5 g/109 mmol per day 3.0 g/130 mmol per day 3.5 g/152 mmol per day 4.0 g/174 mmol per day
Mean difference (95% CI) Mean difference (95% CI) Mean difference (95% CI) Mean difference (95% CI) Mean difference (95% CI)
In general, similar reductions in BP levels were 
achieved by use of interventions that sought to re-
duce sodium intake by diet modification and by initial 
dietary sodium reduction followed by selective target-
ing of sodium intake using different doses of sodium 
supplement pills, with some interesting exceptions. 
Specifically, difference in sodium intake induced by 
sodium supplementations was less effective in modify-
ing both SBP and DBP compared with overall dietary 
change, particularly at low levels of intake (<2 g/d of 
sodium). In contrast, dietary changes proved to be 
more effective in reducing BP at such low levels of so-
dium intake. Dietary change results in modification of 
the overall dietary pattern, which may encompass in-
teractions among multiple modifications of nutrients, 
potentially yielding a greater reduction in BP at very low 
levels of sodium intake, and highlighting the relevance 
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Figure 2. Dose–response meta-analysis of changes in SBP and DBP levels (mm Hg) according to achieved sodium excretion in the treatment and 
control groups at the end of the trials (all studies) and by type of intervention (supplementation or diet).
The average curve (solid line) with 95% confidence limits (dashed lines) was estimated with a 1-stage random-effects restricted cubic spline model, using 2 g/d as 




 http://ahajournals.org by on A
pril 22, 2021
Filippini et al Sodium and BP: Dose–Response














intake alone when dealing with dietary interventions to 
reduce BP levels.129–132 On the other hand, the slightly 
stronger BP decrease induced by selective difference in 
sodium intake at very high levels of intake, as compared 
with broader dietary changes, suggests that the simple 
reduction of sodium intake at such high levels of ex-
posure is a highly effective tool to effectively achieve 
large reduction in BP levels, also being a more feasible 
approach at the population level.
In stratified analyses, we noted an apparent modifi-
cation of the capacity of sodium exposure to increase BP 
according to study design, with a stronger association 
in crossover studies compared with parallel trials only 
at high levels of sodium intake. At low levels of sodium 
intake, failure of crossover trials, in contrast with paral-
lel designed trials, to document a reduction in DBP after 
the sodium restriction could have been attributable to 
the lack of adequate (or any) washout period, although 
such a hypothesis remains speculative. Failure to detect 
sex- and age-specific differences in our dose–response 
meta-analysis is also of interest, suggesting the absence 
of specific susceptibility for these factors to modify the 
effect of sodium reduction on BP, although the number 
of trials for each subgroup was relatively small.
The effect of study duration on the relationship be-
tween sodium reduction and BP is of interest. We ex-
cluded trials with a duration <4 weeks, as done in oth-
er recent reviews and meta-analyses,2,7,8,19,22 because 
many of them have involved extreme and acute non-
physiologic changes in sodium intake, and because 
sodium reduction interventions, especially those based 
on behavioral change, are unlikely to demonstrate 
their full effect in a period <1 month.133 In our analy-
sis, trials with a duration ≥12 weeks showed weaker 
effects on BP compared with trials with a duration 
of 4 to <12 weeks, but the dose–response relation-
ship was still substantially linear and meaningful. Our 
finding that a positive, almost linear dose–response 
Figure 3. Dose–response meta-analysis of changes in SBP and DBP levels (mm Hg) according to achieved sodium excretion in the treatment and 
control groups at the end of the trials divided by hypertension status (no hypertension and hypertension).
The average curve (solid line) with 95% confidence limits (dashed lines) was estimated with a 1-stage random-effects restricted cubic spline model, using 2 g/d as 
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relationship between sodium intake and BP was still 
present, without any evidence of a threshold for ef-
fect, in trials of longer duration conducted in those 
with lower levels of BP has special importance for pop-
ulation intake recommendations and public health, 
given the importance of BP as a risk factor for stroke, 
heart failure, and many other CVD and renal compli-
cations.15,121,128,134 Our analysis also has an important 
advantage over previous meta-analyses such as that 
by Huang et al4 in that we could independently assess 
the effect of duration versus the different intensities of 
sodium reduction in short-term versus long-term trials. 
Because the trials with longer duration had a much 
smaller contrast in sodium intake compared with the 
trials of shorter duration, the previous analyses did not 
generally allow for separation of the effects of dura-
tion versus dose on change in BP.
We also found some evidence that background ha-
bitual sodium intake could influence the relationship 
between changes in sodium intake and level of BP, with 
a greater capacity for high-dose sodium supplementa-
tion to increase BP in those with a higher usual sodium 
intake. This suggests a greater susceptibility to the sodi-
um-driven BP increases after consumption of diets with 
higher sodium content, or conversely that the capacity 
of reductions in dietary sodium to lower BP is enhanced 
in those generally consuming more sodium in their diet.
This meta-analysis has strengths in addition to its key 
feature, the capacity to carry out a comprehensive, flex-
ible dose–response assessment based on RCTs where 
only 2 levels of contrast were studied. We were able to 
include a relatively large number of trials that allowed 
for broad representation of adults, including those with 
and without high BP, and substantial precision for most 
of our estimates. We studied a much wider range of 
dietary sodium exposure than is possible in any individ-
ual trial. Moreover, we excluded trials with a duration 
<4 weeks, allowing for more reliable inferences about 
Figure 4. Dose–response meta-analysis of changes in SBP and DBP levels (mm Hg) according to achieved sodium excretion in the treatment and 
control groups at the end of the trials stratified by trial duration (4–11 weeks or ≥12 weeks).
The average curve (solid line) with 95% confidence limits (dashed lines) was estimated with a 1-stage random-effects restricted cubic spline model, using 2 g/d as 
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the relationship between long-term sodium intake and 
BP. Our findings, particularly those based on the RCTs 
with the longest duration, should closely mirror the ef-
fects of habitual sodium intake on BP. Our findings were 
strengthened by the limited evidence of small-study bias 
in the overall analysis. We acknowledge that such bias 
might have partially affected the analysis in studies based 
on dietary modifications and in those with participants 
who had hypertension.
We are also aware of an important limitation of our me-
ta-analysis, ie, the statistical instability of some point esti-
mates for the highest and lowest dietary sodium exposure, 
particularly for participants without hypertension and, for 
those with hypertension, in trials with the longest duration.
Our analysis does not represent a direct assessment of 
the sodium–CVD risk relationship, a major issue of cardio-
vascular health and more generally human health.135–137 
However, the effect of sodium intake on BP is inherently 
of major interest, given the importance of BP to CVD 
morbidity and mortality, and the use of BP as a surrogate 
end point for CVD.19 Therefore, the findings in this re-
view and dose–response meta-analysis, confirming and 
strengthening previous reports and providing additional 
complementary information by summarizing the entire 
body of the evidence generated by human experimental 
studies, may provide sound evidence to strengthen rec-
ommendations to reduce dietary sodium intake in most 
populations and individuals.138 Even a small increase in 
BP is associated with an increase in CVD risk, including 
for stroke, coronary heart disease, and heart failure.135 
Our results are consistent with the recommendations 
by the US National Academies of Sciences, Engineering, 
and Medicine,19 the European Food Safety Authority,20 
the World Health Organization,13 the American Heart As-
sociation,14,17 and the European Societies of Cardiology 
and of Hypertension18 to limit sodium intake to values 
between 1.5 and 2.3 g/d, supporting the adequacy of 
the lowest among these standards.
Our results confirm a positive relationship between 
sodium intake and average BP in experimental studies 
and indicate that it is largely but not always compatible 
with a linear association over the entire large range of 
exposure experienced by adult trial participants, with 
no suggestion of thresholds at low or high levels of in-
take. The results also suggest this relationship is gen-
erally true for both SBP and DBP, for adults with and 
without hypertension, and during shorter and longer 
periods of sodium reduction.
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Figure 5. Dose–response meta-analysis of changes in SBP and DBP levels (mm Hg) according to the difference in sodium excretion between the 
treatment and the control groups at the end of the trials (all studies) and by type of intervention (supplementation or diet).
The average curve (solid line) with 95% confidence limits (dashed lines) was estimated with a 1-stage random-effects restricted cubic spline model. DBP indicates 
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